BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet J, Brú C, Bruix J. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Semin Liver Dis 1999;19:329-38. [DOI: 10.1055/s-2007-1007122] [Cited by in Crossref: 2268] [Cited by in F6Publishing: 2114] [Article Influence: 162.0] [Reference Citation Analysis]
Number Citing Articles
1 Di Bisceglie AM, Strasberg S. A common staging system for hepatocellular carcinoma. Hepatology 2004;39:550-1. [DOI: 10.1002/hep.20072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
2 De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma 2021;8:57-69. [PMID: 33688489 DOI: 10.2147/JHC.S282062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang ZF, Feng XS, Chen H, Duan ZJ, Wang LX, Yang D, Liu PX, Zhang QP, Jin YL, Sun ZG, Liu H. Prognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resection. BMC Gastroenterol 2016;16:57. [PMID: 27255554 DOI: 10.1186/s12876-016-0474-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
4 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 146] [Article Influence: 21.8] [Reference Citation Analysis]
5 Llovet JM. Evidence-based medicine in the treatment of hepatocellular carcinoma: Evidence-based treatment of HCC. Journal of Gastroenterology and Hepatology 2002;17:S428-33. [DOI: 10.1046/j.1440-1746.17.s3.40.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
6 Mähringer-kunz A, Steinle V, Düber C, Weinmann A, Koch S, Schmidtmann I, Schotten S, Hinrichs JB, Graafen D, Pinto dos Santos D, Galle PR, Kloeckner R. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? Liver Int 2019;39:324-31. [DOI: 10.1111/liv.13988] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
7 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Rogério CPA, Daniele A, Betty G, Carla M, Monica V, Michele H, Deborah T, Mario K, Otavio G, Paula P. Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Annals of Hepatology 2011;10:21-7. [DOI: 10.1016/s1665-2681(19)31582-0] [Cited by in Crossref: 53] [Article Influence: 4.8] [Reference Citation Analysis]
9 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Sanampudi S, Yu Q, Raissi D. Percutaneous microwave ablation of hepatic lesions near the heart. Transl Gastroenterol Hepatol 2021;6:59. [PMID: 34805581 DOI: 10.21037/tgh-20-314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology. 2014;59:1415-1426. [PMID: 24002931 DOI: 10.1002/hep.26731] [Cited by in Crossref: 177] [Cited by in F6Publishing: 181] [Article Influence: 22.1] [Reference Citation Analysis]
12 Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Annals of Hepatology 2013;12:915-25. [DOI: 10.1016/s1665-2681(19)31297-9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Varotti G, Ramacciato G, Ercolani G, Grazi GL, Vetrone G, Cescon M, Del Gaudio M, Ravaioli M, Ziparo V, Lauro A, Pinna A. Comparison between the fifth and sixth editions of the AJCC/UICC TNM staging systems for hepatocellular carcinoma: multicentric study on 393 cirrhotic resected patients. Eur J Surg Oncol 2005;31:760-7. [PMID: 15975760 DOI: 10.1016/j.ejso.2005.04.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
14 Welker MW, Trojan J. Anti-angiogenesis in hepatocellular carcinoma treatment: Current evidence and future perspectives. World J Gastroenterol 2011; 17(26): 3075-3081 [PMID: 21912449 DOI: 10.3748/wjg.v17.i26.3075] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
15 Xue F, Shi S, Zhang Z, Xu C, Zheng J, Qin T, Qian Z, Zhao X, Tong Y, Xia L, Xia Q. Application of a novel liquid biopsy in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol Lett 2018;15:5481-8. [PMID: 29552189 DOI: 10.3892/ol.2018.8019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
16 Yang S, Yan HL, Tao QF, Yuan SX, Tang GN, Yang Y, Wang LL, Zhang YL, Sun SH, Zhou WP. Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. J Cancer Res Clin Oncol. 2014;140:109-116. [PMID: 24240726 DOI: 10.1007/s00432-013-1536-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
17 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Carloni V, Luong TV, Rombouts K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 2014;34:834-843. [PMID: 24397349 DOI: 10.1111/liv.12465] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
19 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Reference Citation Analysis]
20 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
21 Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. The American Journal of Surgery 2012;203:101-6. [DOI: 10.1016/j.amjsurg.2010.09.030] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
22 Chevallier P, Baudin G, Anty R, Guibal A, Chassang M, Avril L, Tran A. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagnostic and Interventional Imaging 2015;96:637-46. [DOI: 10.1016/j.diii.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
23 Martini G, Ciardiello D, Paragliola F, Nacca V, Santaniello W, Urraro F, Stanzione M, Niosi M, Dallio M, Federico A, Selvaggi F, Della Corte CM, Napolitano S, Ciardiello F, Martinelli E. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4719. [PMID: 34572944 DOI: 10.3390/cancers13184719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Díaz-Sánchez A, Matilla A, Núñez O, Merino B, Peligros I, Rincón D, Salcedo M, Lo Iacono O, Vega Catalina M, Clemente G, Bañares R. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival]. Gastroenterol Hepatol 2010;33:155-64. [PMID: 19945770 DOI: 10.1016/j.gastrohep.2009.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Lu LC, Shao YY, Kuo RN, Lin ZZ, Yeh YC, Shau WY, Hsu CH, Cheng AL, Lai MS. Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. Cancer 2013;119:1210-6. [PMID: 23212657 DOI: 10.1002/cncr.27800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
26 Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24:307-315. [PMID: 23375519 DOI: 10.1016/j.jvir.2012.11.026] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
27 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
28 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
29 Sciarra A, Pintea B, Nahm JH, Donadon M, Morenghi E, Maggioni M, Blanc JF, Torzilli G, Yeh M, Bioulac-Sage P, Park YN, Roncalli M, Di Tommaso L. CYP1A2 is a predictor of HCC recurrence in HCV-related chronic liver disease: A retrospective multicentric validation study. Dig Liver Dis 2017;49:434-9. [PMID: 28040498 DOI: 10.1016/j.dld.2016.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
30 Cao C, Wang C. Clinical significance of serum miR-768-3p in HBV-related hepatocellular carcinoma and its potential mechanism. Clin Exp Med 2020;20:569-76. [PMID: 32712720 DOI: 10.1007/s10238-020-00646-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 3.7] [Reference Citation Analysis]
32 Burgmans MC, Too CW, Fiocco M, Kerbert AJ, Lo RH, Schaapman JJ, van Erkel AR, Coenraad MJ, Tan BS. Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2016;39:1708-15. [PMID: 27671151 DOI: 10.1007/s00270-016-1462-7] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, La Mura V, Colombo M, Lampertico P. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int 2018;38:1624-34. [DOI: 10.1111/liv.13888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
34 Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, Lin J, Zhang J, Zhang M, Zhang L, Xie X, Guo K, Ren Z, Lin S, Zhang B. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A retrospective analysis of 509 cases. Medicine (Baltimore) 2017;96:e7438. [PMID: 28700480 DOI: 10.1097/MD.0000000000007438] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Forner A, Díaz-gonzález Á, Liccioni A, Vilana R. Prognosis prediction and staging. Best Practice & Research Clinical Gastroenterology 2014;28:855-65. [DOI: 10.1016/j.bpg.2014.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
36 Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL;  KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38:193-202. [PMID: 31790344 DOI: 10.1200/jco.19.01307] [Cited by in Crossref: 317] [Cited by in F6Publishing: 219] [Article Influence: 105.7] [Reference Citation Analysis]
37 Chang L, Wang Y, Zhang J, Guo T. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget 2017;8:20418-27. [PMID: 28099898 DOI: 10.18632/oncotarget.14668] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
38 Kang SH, Kim do Y, Jeon SM, Ahn SH, Park JY, Kim SU, Kim JK, Lee KS, Chon CY, Han KH. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol. 2012;24:849-856. [PMID: 22495400 DOI: 10.1097/meg.0b013e3283535c34] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
39 Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D’Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 2008;206:281-291. [PMID: 18222381 DOI: 10.1016/j.jamcollsurg.2007.07.031] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
40 Ahn S, Hyeon J, Park CK. Notch1 and Notch4 are markers for poor prognosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:286-294. [PMID: 23742774 DOI: 10.1016/s1499-3872(13)60046-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
41 Woo HY, Heo J, Yoon KT, Kim GH, Kang DH, Song GA, Cho M. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma. Scand J Gastroenterol 2012;47:809-19. [PMID: 22563643 DOI: 10.3109/00365521.2012.683040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
42 Fang JZ, Yang Y, Zhu HD, Sun JN, Mi HC, Lu CD. Surgical Treatment of Postoperative Abdominal Metastases of Hepatocellular Carcinoma: 10-Year Experience in a Single Center. Cancer Manag Res 2021;13:8673-83. [PMID: 34849024 DOI: 10.2147/CMAR.S328250] [Reference Citation Analysis]
43 Yang T, Zhang H, Shen YN, Wu MC, Shen F, Schwartz M. Combination therapy with sorafenib and radiofrequency ablation for BCLC stage 0-B1 hepatocellular carcinoma. Am J Gastroenterol 2015;110:595. [PMID: 25853196 DOI: 10.1038/ajg.2015.33] [Reference Citation Analysis]
44 Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol. 2014;21:971-978. [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
45 Gaia S, Ciruolo M, Ribaldone DG, Rolle E, Migliore E, Mosso E, Vola S, Risso A, Fagoonee S, Saracco GM, Carucci P. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. Curr Oncol 2021;28:1034-44. [PMID: 33669107 DOI: 10.3390/curroncol28020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Chan WH, Huang SF, Lee CW, Wu TH, Pan KT, Lin SM, Yu MC, Hung CF. Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study. J Int Med Res 2019;47:4862-71. [PMID: 31446817 DOI: 10.1177/0300060519866941] [Reference Citation Analysis]
47 Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129-134. [PMID: 24870698 DOI: 10.1007/s00270-014-0907-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
48 Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck-radosavljevic M. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261-73. [DOI: 10.1002/hep.26256] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 20.2] [Reference Citation Analysis]
49 Vlasoff DM, Baschinsky DY, De Young BR, Morrison CD, Nuovo GJ, Frankel WL. C-erb B2 (Her2/ neu) Is Neither Overexpressed nor Amplified in Hepatic Neoplasms: . Applied Immunohistochemistry & Molecular Morphology 2002;10:237-41. [DOI: 10.1097/00129039-200209000-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
50 Cillo U, Vitale A, Navaglia F, Basso D, Montin U, Bassanello M, D'Amico F, Ciarleglio FA, Brolese A, Zanus G, De Pascale V, Plebani M, D'Amico DF. Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatocellular carcinoma. World J Gastroenterol 2005;11:6920-5. [PMID: 16437593 DOI: 10.3748/wjg.v11.i44.6920] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
51 Harimoto N, Araki K, Muranushi R, Hoshino K, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, Watanabe A, Shirabe K. Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection. Hepatol Res 2021. [PMID: 34761491 DOI: 10.1111/hepr.13730] [Reference Citation Analysis]
52 Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:517-523. [PMID: 31524775 DOI: 10.1097/MEG.0000000000001528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2012;35:765-74. [DOI: 10.1007/s00270-012-0423-z] [Reference Citation Analysis]
54 Samir N, Matboli M, El-Tayeb H, El-Tawdi A, Hassan MK, Waly A, El-Akkad HAE, Ramadan MG, Al-Belkini TN, El-Khamisy S, El-Asmar F. Competing endogenous RNA network crosstalk reveals novel molecular markers in colorectal cancer. J Cell Biochem 2018;119:6869-81. [PMID: 29737552 DOI: 10.1002/jcb.26884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
55 Zhang F, Lu S, Tian M, Hu K, Chen R, Zhang B, Ren Z, Shi Y, Yin X. Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma. J Cancer 2020;11:5177-86. [PMID: 32742464 DOI: 10.7150/jca.45633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
56 Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita H, Kuramitsu K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today. 2017;47:1094-1103. [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
57 Gómez Rodríguez R, Romero Gutiérrez M, González de Frutos C, de Artaza Varasa T, de la Cruz Perez G, Ciampi Dopazo JJ, Lanciego Pérez C, Gómez Moreno AZ. [Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients]. Gastroenterol Hepatol. 2011;34:524-531. [PMID: 21940068 DOI: 10.1016/j.gastrohep.2011.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
58 Bonnetain F, Paoletti X, Collette S, Doffoel M, Bouché O, Raoul JL, Rougier P, Masskouri F, Barbare JC, Bedenne L. Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res 2008;17:831-43. [PMID: 18618292 DOI: 10.1007/s11136-008-9365-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
59 Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma. Mol Clin Oncol 2017;6:566-74. [PMID: 28413670 DOI: 10.3892/mco.2017.1166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
60 Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Granito A, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cammà C, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017;37:259-70. [PMID: 27427866 DOI: 10.1111/liv.13204] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
61 Al-Khaykanee AM, Abdel-Rahman AA, Essa A, Gadallah AA, Ali BH, Al-Aqar AA, Badr EAE, Shehab-Eldeen S. Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101636. [PMID: 33740609 DOI: 10.1016/j.clinre.2021.101636] [Reference Citation Analysis]
62 Zhang T, Luo H, Cui X, Zhang W, Zhang L, Chen X, Li K. Ultrasound-Guided Percutaneous Microwave Ablation Treatment of Initial Recurrent Hepatocellular Carcinoma after Hepatic Resection: Long-Term Outcomes. Ultrasound in Medicine & Biology 2015;41:2391-9. [DOI: 10.1016/j.ultrasmedbio.2015.04.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res. 2012;42:340-348. [PMID: 22151009 DOI: 10.1111/j.1872-034x.2011.00938.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
64 Omata M, Dan Y, Daniele B, Plentz R, Rudolph KL, Manns M, Piratvisuth T, Chen DS, Tateishi R, Chutaputti A. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries: Comparison of HCC from different countries. Journal of Gastroenterology and Hepatology 2002;17:S40-9. [DOI: 10.1046/j.1440-1746.17.s1.14.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
65 Shindoh J, Vauthey JN. Staging of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:313-322. [PMID: 24560112 DOI: 10.1016/j.soc.2013.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
66 Escarda A, Vaquer P, Bonet L, Miralbés S, Gómez C, Obrador A. [Clivus metastasis from hepatocarcinoma associated with transarterial hepatic chemoembolization]. Gastroenterol Hepatol 2006;29:401-4. [PMID: 16938255 DOI: 10.1157/13091453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
67 Rimini M, Shimose S, Lonardi S, Tada T, Masi G, Iwamoto H, Lai E, Burgio V, Hiraoka A, Ishikawa T, Soldà C, Shirono T, Vivaldi C, Takaguchi K, Shimada N, Astara G, Koga H, Nouso K, Joko K, Torimura T, Hiasa Y, Salani F, Scartozzi M, Cascinu S, Casadei-Gardini A. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. Hepatol Res 2021;51:1229-41. [PMID: 34591334 DOI: 10.1111/hepr.13718] [Reference Citation Analysis]
68 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
69 Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52. [PMID: 19908093 DOI: 10.1007/s00270-099-9711-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
71 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
72 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
73 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
74 Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol 2012;6:441-4. [PMID: 22928896 DOI: 10.1586/egh.12.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
75 Tannus RK, Almeida-Carvalho SR, Loureiro-Matos CA, Miziara-Gonzalez A, Salzedas-Netto AA, Szejnfeld D, D'Ippolito G, Pereira-Lanzoni V, Souza-Silva I. Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems. PLoS One 2018;13:e0194922. [PMID: 29617435 DOI: 10.1371/journal.pone.0194922] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
76 Gao R, Gabr A, Mouli S, Riaz A, Kulik L, Lewandowski RJ, Salem R. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study. J Vasc Interv Radiol 2020;31:401-408.e1. [PMID: 31983593 DOI: 10.1016/j.jvir.2019.08.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
77 Santos J, Valencia E; Panel de Expertos de GeSIDA. [Consensus statement on the clinical management of non-AIDS defining malignancies. GeSIDA expert panel]. Enferm Infecc Microbiol Clin 2014;32:515-22. [PMID: 24953385 DOI: 10.1016/j.eimc.2014.04.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
78 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
79 Lee DY, Park JW, Kim TH, Lee JH, Kim BH, Woo SM, Kim SS, Lee WJ, Kim DY, Kim CM. Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlenther Onkol 2015;191:835-44. [PMID: 26174506 DOI: 10.1007/s00066-015-0873-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
80 Shiozawa K, Watanabe M, Ikehara T, Matsukiyo Y, Kogame M, Kishimoto Y, Okubo Y, Makino H, Tsukamoto N, Igarashi Y, Sumino Y. Comparison of percutaneous radiofrequency ablation and CyberKnife® for initial solitary hepatocellular carcinoma: A pilot study. World J Gastroenterol 2015; 21(48): 13490-13499 [PMID: 26730160 DOI: 10.3748/wjg.v21.i48.13490] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
81 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
82 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
83 Kaufmann S, Horger T, Oelker A, Beck S, Schulze M, Nikolaou K, Ketelsen D, Horger M. Volume perfusion computed tomography (VPCT)-based evaluation of response to TACE using two different sized drug eluting beads in patients with nonresectable hepatocellular carcinoma: Impact on tumor and liver parenchymal vascularisation. Eur J Radiol 2015;84:2548-54. [PMID: 26428842 DOI: 10.1016/j.ejrad.2015.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
84 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int. 2013;26:109-118. [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
85 Hsu C, Liu P, Lee Y, Hsia C, Huang Y, Chiou Y, Tsai Y, Nagaria TS, Huo T. Aggressive Therapeutic Strategies Improve the Survival of Hepatocellular Carcinoma Patients with Performance Status 1 or 2: A Propensity Score Analysis. Ann Surg Oncol 2015;22:1324-31. [DOI: 10.1245/s10434-014-4151-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
86 Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M. Reply to Letter: “A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group”: When the Study Setting “Ignores” the Patients. Ann Surg. 2015;262:e30-e31. [PMID: 24253157 DOI: 10.1097/sla.0000000000000382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
87 Yang T, Lau WY, Zhang H, Huang B, Lu JH, Wu MC. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons’ perspective. World J Gastroenterol 2015; 21(27): 8256-8261 [PMID: 26217077 DOI: 10.3748/wjg.v21.i27.8256] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
88 Bhoori S, Schiavo M, Russo A, Mazzaferro V. First-line treatment for hepatocellular carcinoma: resection or transplantation? Transplant Proc. 2007;39:2271-2273. [PMID: 17889160 DOI: 10.1016/j.transproceed.2007.06.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
89 Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. Journal of Hepatology 2007;47:527-37. [DOI: 10.1016/j.jhep.2007.06.010] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 11.1] [Reference Citation Analysis]
90 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther 2020;13:10267-73. [PMID: 33116607 DOI: 10.2147/OTT.S261521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
93 He Q, Jiang JJ, Jiang YX, Wang WT, Yang L; Liver Surgery Group. Health-Related Quality of Life Comparisons After Radical Therapy for Early-Stage Hepatocellular Carcinoma. Transplant Proc 2018;50:1470-4. [PMID: 29880373 DOI: 10.1016/j.transproceed.2018.04.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
94 Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2019;23:76-83. [DOI: 10.1007/s11605-018-3871-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
95 Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology 2016;151:1062-5. [PMID: 27983951 DOI: 10.1053/j.gastro.2016.10.031] [Reference Citation Analysis]
96 Safcak D, Drazilova S, Gazda J, Andrasina I, Adamcova-Selcanova S, Barila R, Mego M, Rac M, Skladany L, Zigrai M, Janicko M, Jarcuska P. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Clinical Patterns, Outcomes, and Prognostic Factors for Overall Survival-A Retrospective Analysis of a Slovak Cohort. J Clin Med 2021;10:3186. [PMID: 34300352 DOI: 10.3390/jcm10143186] [Reference Citation Analysis]
97 Xu L, Wu J, Lu W, Yang C, Liu H. Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Transplant Proc. 2019;51:3338-3346. [PMID: 31732203 DOI: 10.1016/j.transproceed.2019.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
98 Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP. Laparoscopic liver resection for huge (≥10 cm) hepatocellular carcinoma: A coarsened exact-matched single-surgeon study. Surg Oncol 2021;37:101569. [PMID: 33839442 DOI: 10.1016/j.suronc.2021.101569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, Simpson W, Facciuto L, Patel RS, Gunasekaran G, Kim E, Schiano TD, Facciuto ME. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery 2021;169:1044-51. [PMID: 33648768 DOI: 10.1016/j.surg.2020.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
101 Ma X, Cui Y, Zhou H, Li Q. Function of mitochondrial pyruvate carriers in hepatocellular carcinoma patients. Oncol Lett 2018;15:9110-6. [PMID: 29805642 DOI: 10.3892/ol.2018.8466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Dasari BV, Kamarajah SK, Hodson J, Pawlik TM, Vauthey JN, Ma YT, Punia P, Coldham C, Abradelo M, Roberts KJ, Marudanayagam R, Sutcliffe RP, Muiesan P, Mirza DF, Isaac J. Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver. HPB (Oxford). 2020;22:383-390. [PMID: 31416786 DOI: 10.1016/j.hpb.2019.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
103 Dakhoul L, Gawrieh S, Jones KR, Ghabril M, McShane C, Orman E, Vilar-Gomez E, Chalasani N, Nephew L. Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. Hepatol Commun 2019;3:52-62. [PMID: 30619994 DOI: 10.1002/hep4.1277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
104 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
105 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D; Cochrane Hepato-Biliary Group. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013362] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
106 Shu QH, Ge YS, Xu GL, Ma JL, Jia WD, Yu JH, Zhang CH, Liu WB. Clinical significance of expression of CD68 and CD11c in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(22): 3538-3547 [DOI: 10.11569/wcjd.v23.i22.3538] [Reference Citation Analysis]
107 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
108 Schütte K, Bornschein J, Kahl S, Seidensticker R, Arend J, Ricke J, Malfertheiner P. Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer 2012;1:257-66. [PMID: 24159590 DOI: 10.1159/000343840] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
109 Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29:3949-3952. [PMID: 21911718 DOI: 10.1200/jco.2011.37.9651] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
110 Singal AG, Patibandla S, Obi J, Fullington H, Parikh ND, Yopp AC, Marrero JA. Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1925-1932.e1. [PMID: 32920214 DOI: 10.1016/j.cgh.2020.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
111 Lee YS, Seo YS, Kim JH, Lee J, Kim HR, Yoo YJ, Kim TS, Kang SH, Suh SJ, Joo MK, Jung YK, Lee BJ, Yim HJ, Yeon JE, Kim JS, Park JJ, Um SH, Bak YT, Byun KS. Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. Gut Liver. 2018;12:94-101. [PMID: 28873509 DOI: 10.5009/gnl17040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
112 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
113 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
114 Welte S, Urbanik T, Elßner C, Kautz N, Koehler BC, Waldburger N, Bermejo JL, Pinna F, Weiss KH, Schemmer P, Jaeger D, Longerich T, Breuhahn K, Schulze-Bergkamen H. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma. PLoS One 2014;9:e110591. [PMID: 25329885 DOI: 10.1371/journal.pone.0110591] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
115 Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631-1639. [PMID: 23547075 DOI: 10.1200/jco.2012.44.1659] [Cited by in Crossref: 445] [Cited by in F6Publishing: 215] [Article Influence: 49.4] [Reference Citation Analysis]
116 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 67.5] [Reference Citation Analysis]
117 Barry A, Apisarnthanarax S, O'Kane GM, Sapisochin G, Beecroft R, Salem R, Yoon SM, Lim YS, Bridgewater J, Davidson B, Scorsetti M, Solbiati L, Diehl A, Schuffenegger PM, Sham JG, Cavallucci D, Galvin Z, Dawson LA, Hawkins MA. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020;5:765-775. [PMID: 32511951 DOI: 10.1016/s2468-1253(20)30182-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
118 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
119 Vallati GE, Trobiani C, Teodoli L, Lai Q, Cappelli F, Ungania S, Catalano C, Lucatelli P. Sarcopenia Worsening One Month after Transarterial Radioembolization Predicts Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. Biology (Basel) 2021;10:728. [PMID: 34439960 DOI: 10.3390/biology10080728] [Reference Citation Analysis]
120 Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci. 2011;56:578-585. [PMID: 21046244 DOI: 10.1007/s10620-010-1444-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
121 Liu TA, Jan YJ, Ko BS, Wu YJ, Lu YJ, Liang SM, Liu CC, Chen SC, Wang J, Shyue SK, Liou JY. Regulation of aldo-keto-reductase family 1 B10 by 14-3-3ε and their prognostic impact of hepatocellular carcinoma. Oncotarget 2015;6:38967-82. [PMID: 26516929 DOI: 10.18632/oncotarget.5734] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
122 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, Kim WT. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9:534-540. [PMID: 19039270 DOI: 10.3348/kjr.2008.9.6.534] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
124 Sheiman RG, Mullan C, Ahmed M. In vivo determination of a modified heat capacity of small hepatocellular carcinomas prior to radiofrequency ablation: Correlation with adjacent vasculature and tumour recurrence. International Journal of Hyperthermia 2012;28:122-31. [DOI: 10.3109/02656736.2011.642457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
125 Dercle L, Ma J, Xie C, Chen AP, Wang D, Luk L, Revel-Mouroz P, Otal P, Peron JM, Rousseau H, Lu L, Schwartz LH, Mokrane FZ, Zhao B. Using a single abdominal computed tomography image to differentiate five contrast-enhancement phases: A machine-learning algorithm for radiomics-based precision medicine. Eur J Radiol 2020;125:108850. [PMID: 32070870 DOI: 10.1016/j.ejrad.2020.108850] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
126 Liang LJ, Hu WJ, Yin XY, Zhou Q, Peng BG, Li DM, Lu MD. Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy. World J Surg. 2008;32:627-631. [PMID: 18228094 DOI: 10.1007/s00268-007-9364-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
127 Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2019;17:595-606. [PMID: 30273751 DOI: 10.1016/j.cgh.2018.09.043] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
128 Casellas-Robert M, Lim C, Lopez-Ben S, Lladó L, Salloum C, Codina-Font J, Comas-Cufí M, Ramos E, Figueras J, Azoulay D. Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study. World J Surg 2020;44:3915-22. [PMID: 32661688 DOI: 10.1007/s00268-020-05687-9] [Reference Citation Analysis]
129 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
130 Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 2017;27:526-35. [PMID: 27277261 DOI: 10.1007/s00330-016-4445-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
131 Liu S, Xu Z, Fang Z, Zhang D, Qin Z, Fan L, Duan J, Yin H, Zhang Y, Pang Q, Tan Y. The Combination of Age, International Standardized Ratio, Albumin and γ-Glutamyl Transpeptidase (AIAG), Tumor Size and Alpha Fetoprotein (AFP) Stage as the Prognostic Model for Hepatitis B-Related Hepatocellular Carcinoma. Int J Gen Med 2021;14:4291-301. [PMID: 34408472 DOI: 10.2147/IJGM.S323293] [Reference Citation Analysis]
132 Saito M, Seo Y, Yano Y, Momose K, Hirano H, Yoshida M, Azuma T. Reduction in non-protein respiratory quotient is related to overall survival after hepatocellular carcinoma treatment. PLoS One 2013;8:e55441. [PMID: 23520445 DOI: 10.1371/journal.pone.0055441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554. [PMID: 17133492 DOI: 10.1002/hep.21415] [Cited by in Crossref: 252] [Cited by in F6Publishing: 243] [Article Influence: 16.8] [Reference Citation Analysis]
134 Fuster J. Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? Hepat Oncol 2015;2:245-53. [PMID: 30191006 DOI: 10.2217/hep.15.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Yang H, Seon J, Sung PS, Oh JS, Lee HL, Jang B, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. Journal of Vascular and Interventional Radiology 2017;28:1503-1511.e2. [DOI: 10.1016/j.jvir.2017.07.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
136 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 100] [Article Influence: 6.8] [Reference Citation Analysis]
137 Lee YJ, Hah YJ, Kang YN, Kang KJ, Hwang JS, Chung WJ, Cho KB, Park KS, Kim ES, Seo HY, Kim MK, Park KG, Jang BK. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One 2013;8:e81540. [PMID: 24282606 DOI: 10.1371/journal.pone.0081540] [Cited by in Crossref: 48] [Cited by in F6Publishing: 54] [Article Influence: 5.3] [Reference Citation Analysis]
138 Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, Peng T, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver Int. 2015;35:999-1009. [PMID: 24461059 DOI: 10.1111/liv.12460] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
139 Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg. 2009;249:799-805. [PMID: 19387322 DOI: 10.1097/sla.0b013e3181a38eb5] [Cited by in Crossref: 185] [Cited by in F6Publishing: 78] [Article Influence: 14.2] [Reference Citation Analysis]
140 Hernandez-Meza G, Violi NV, Said D, Novogrodsky E, Villavisanis D, Maron SZ, Frere J, Schiano TD, Friedman S, Boffetta P, Branch A, Taouli B. MRI is the most commonly used imaging modality for HCC screening at a tertiary care transplant center. Abdom Radiol (NY) 2021. [PMID: 34283266 DOI: 10.1007/s00261-021-03212-7] [Reference Citation Analysis]
141 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
142 Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, Redaelli A, Chiesa A, Silini EM, Almasio PL, Maisonneuve P. Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study. Am J Gastroenterol 2009;104:1147-58. [DOI: 10.1038/ajg.2009.31] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 8.8] [Reference Citation Analysis]
143 Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, Kirstein MM, Marquardt S, Rodt T. Health-Related Quality of Life in Patients with Hepatocellular Carcinoma Treated with Initial Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2017;40:1559-66. [PMID: 28488104 DOI: 10.1007/s00270-017-1681-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
144 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19(21): 3207-3216 [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
145 Chan KM, Lee CF, Wu TJ, Chou HS, Yu MC, Lee WC, Chen MF. Adverse outcomes in patients with postoperative ascites after liver resection for hepatocellular carcinoma. World J Surg. 2012;36:392-400. [PMID: 22131090 DOI: 10.1007/s00268-011-1367-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
146 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, Suh DJ. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010;78:180-187. [PMID: 19926229 DOI: 10.1016/j.ijrobp.2009.07.1730] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
148 Kolarich AR, Cabrera R, Hughes SJ, George TJ, Geller BS, Grajo JR. Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis. HPB 2019;21:249-57. [DOI: 10.1016/j.hpb.2018.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
149 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 801] [Cited by in F6Publishing: 753] [Article Influence: 40.1] [Reference Citation Analysis]
150 Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, Pesenti C, Ratone JP, Bernard JP, Gerolami R, Giovannini M. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21-7. [PMID: 26056497 DOI: 10.2147/HMER.S67940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
151 Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett. 2015;9:1628-1632. [PMID: 25789012 DOI: 10.3892/ol.2015.2960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
152 Huo TI, Hsia CY, Huang YH, Lin HC, Lee PC, Lui WY, Chiang JH, Chiou YY, Loong CC, Lee SD. Selecting a short-term prognostic model for hepatocellular carcinoma: comparison between the model for end-stage liver disease (MELD), MELD-sodium, and five cancer staging systems. J Clin Gastroenterol. 2009;43:773-781. [PMID: 19262404 DOI: 10.1097/mcg.0b013e31818dd962] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
153 Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology. 2008;134:1831-1835. [PMID: 18486619 DOI: 10.1053/j.gastro.2008.05.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
154 Di Sandro S, Lauterio A, Giacomoni A, Concone G, Mangoni I, Mihaylov P, De Carlis L. Totally robotic liver resection for hepatocellular carcinoma in cirrhotic patients: safety and feasibility. J Robotic Surg 2014;8:357-64. [DOI: 10.1007/s11701-014-0479-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
155 Pinato DJ. Breaking Kuhn's paradigm in advanced hepatocellular carcinoma. Hepatology 2018;67:1663-5. [DOI: 10.1002/hep.29714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
156 Beebe SJ. Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields. J Hepatocell Carcinoma 2015;2:49-55. [PMID: 27508194 DOI: 10.2147/JHC.S83941] [Reference Citation Analysis]
157 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
158 Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. J Gastroenterol Hepatol 2019;34:2179-86. [PMID: 31062879 DOI: 10.1111/jgh.14705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
159 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
160 Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 2014;9:e103228. [PMID: 25133493 DOI: 10.1371/journal.pone.0103228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
161 González HD, Figueras J. Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy. Clin Transl Oncol 2009;11:20-7. [DOI: 10.1007/s12094-009-0306-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Takemura N, Aoki T, Hasegawa K, Kaneko J, Arita J, Akamatsu N, Makuuchi M, Kokudo N. Hepatectomy for hepatocellular carcinoma after perioperative management of portal hypertension. British Journal of Surgery 2019;106:1066-74. [DOI: 10.1002/bjs.11153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
163 Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D'amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D'amico DF. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? Journal of Hepatology 2004;40:124-31. [DOI: 10.1016/j.jhep.2003.09.027] [Cited by in Crossref: 133] [Cited by in F6Publishing: 122] [Article Influence: 7.4] [Reference Citation Analysis]
164 Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, Larson JJ, Pedersen RA, Therneau TM, Gores GJ. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56:614-621. [PMID: 22370914 DOI: 10.1002/hep.25680] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
165 Wu L, Liang Y, Zhang C, Wang X, Ding X, Huang C, Liang H. Prognostic significance of lymphovascular infiltration in overall survival of gastric cancer patients after surgery with curative intent. Chin J Cancer Res 2019;31:785-96. [PMID: 31814682 DOI: 10.21147/j.issn.1000-9604.2019.05.08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
166 Abdel-Hafiz SM, Hamdy HE, Khorshed FM, Aboushousha TS, Safwat G, Saber MA, Seleem M, Soliman AH. Evaluation of Osteopontin as a Biomarker in Hepatocellular Carcinomas in Egyptian Patients with Chronic HCV Cirrhosis. Asian Pac J Cancer Prev 2018;19:1021-7. [PMID: 29693976 DOI: 10.22034/APJCP.2018.19.4.1021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Takamoto T, Sugawara Y, Hashimoto T, Makuuchi M. Evaluating the current surgical strategies for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2016;10:341-57. [PMID: 26558422 DOI: 10.1586/17474124.2016.1116381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
168 Meischl T, Rasoul-Rockenschaub S, Györi G, Sieghart W, Reiberger T, Trauner M, Soliman T, Berlakovich G, Pinter M. C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. PLoS One 2019;14:e0216677. [PMID: 31141535 DOI: 10.1371/journal.pone.0216677] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
169 Moya Herráiz A, Torres-Quevedo R, Mir Pallardó J. [Liver transplant in patients with hepatocellular carcinoma]. Cir Esp 2008;84:117-24. [PMID: 18783669 DOI: 10.1016/s0009-739x(08)72152-3] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
170 Bauschke A, Altendorf-Hofmann A, Kissler H, Koch A, Malessa C, Settmacher U. Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation. J Cancer Res Clin Oncol 2017;143:2595-605. [PMID: 28849266 DOI: 10.1007/s00432-017-2507-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
171 Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B, Chen KF. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. J Surg Res 2016;200:82-90. [PMID: 26259778 DOI: 10.1016/j.jss.2015.06.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
172 Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: Present and future. Med Clin (Barc). 2018;150:390-397. [PMID: 29096967 DOI: 10.1016/j.medcli.2017.08.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
173 Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, Minqing X, Jiaying Y. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180. [PMID: 25474433 DOI: 10.1097/MD.0000000000000180] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
174 Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009;20 Suppl 7:vii1-vii6. [PMID: 19497945 DOI: 10.1093/annonc/mdp281] [Cited by in Crossref: 54] [Cited by in F6Publishing: 64] [Article Influence: 4.2] [Reference Citation Analysis]
175 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
176 Knox JJ. Addressing the Interplay of Liver Disease and Hepatocellular Carcinoma on Patient Survival: The ALBI Scoring Model. JCO 2015;33:529-31. [DOI: 10.1200/jco.2014.59.0521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
177 Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR. Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT. J Nucl Med 2015;56:1661-6. [PMID: 26405170 DOI: 10.2967/jnumed.115.158758] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
178 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Dong C, Liu Y, Jiang K, Wang H, Qu W, Zhang C, Liang R, Gao Z, Zhao B, Miao Q, Shao S, Wang L. The Nogo-B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. J Cell Biochem 2018;119:7738-46. [PMID: 29904947 DOI: 10.1002/jcb.27125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
180 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021;21:1157. [PMID: 34715816 DOI: 10.1186/s12885-021-08904-3] [Reference Citation Analysis]
181 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
182 Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. The Lancet 2002;359:1734-9. [DOI: 10.1016/s0140-6736(02)08649-x] [Cited by in Crossref: 2274] [Cited by in F6Publishing: 844] [Article Influence: 113.7] [Reference Citation Analysis]
183 Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Reference Citation Analysis]
184 Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Kodama K, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. Clin J Gastroenterol 2020;13:867-72. [PMID: 32020539 DOI: 10.1007/s12328-020-01099-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
185 Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437-1445. [PMID: 19408012 DOI: 10.1007/s00432-009-0588-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
186 Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. J Clin Oncol 2017;35:3575-81. [PMID: 28872925 DOI: 10.1200/JCO.2017.73.8245] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 9.6] [Reference Citation Analysis]
187 Samad NA, Abdul AB, Rahman HS, Rasedee A, Tengku Ibrahim TA, Keon YS. Zerumbone Suppresses Angiogenesis in HepG2 Cells through Inhibition of Matrix Metalloproteinase-9, Vascular Endothelial Growth Factor, and Vascular Endothelial Growth Factor Receptor Expressions. Pharmacogn Mag 2018;13:S731-6. [PMID: 29491625 DOI: 10.4103/pm.pm_18_17] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
188 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
189 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 7.7] [Reference Citation Analysis]
190 Choi W, Yu SJ, Ahn H, Cho H, Cho YY, Lee M, Yoo J, Cho Y, Lee DH, Cho EJ, Lee J, Kim YJ, Yoon J. A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma? Digestive and Liver Disease 2017;49:1273-9. [DOI: 10.1016/j.dld.2017.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
191 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
192 Broelsch CE, Frilling A, Malago M. Hepatoma—resection or transplantation. Surgical Clinics of North America 2004;84:495-511. [DOI: 10.1016/j.suc.2003.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
193 Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36:1913-1921. [PMID: 29498924 DOI: 10.1200/jco.2017.76.0892] [Cited by in Crossref: 218] [Cited by in F6Publishing: 99] [Article Influence: 54.5] [Reference Citation Analysis]
194 Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013;24:2565-2570. [PMID: 23857958 DOI: 10.1093/annonc/mdt247] [Cited by in Crossref: 164] [Cited by in F6Publishing: 145] [Article Influence: 18.2] [Reference Citation Analysis]
195 Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, Shi J, Wu MC, Lau WY, Cheng SQ. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9:717-728. [PMID: 33299827 DOI: 10.21037/hbsn.2019.10.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707-716. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 443] [Cited by in F6Publishing: 405] [Article Influence: 26.1] [Reference Citation Analysis]
197 Hafeez M, Nadeem M, Ahmed M, Faheem-Ur-Rehman. Hepatocellular Carcinoma (HCC), Where do we stand? Current situation. Pak J Med Sci 2020;36:344-8. [PMID: 32292431 DOI: 10.12669/pjms.36.3.1594] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Ko CJ, Chien SY, Chou CT, Chen LS, Chen ML, Chen YL. Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients following hepatic resection. Can J Gastroenterol 2011;25:485-91. [PMID: 21912759 DOI: 10.1155/2011/790528] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
199 Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922. [PMID: 17522517 DOI: 10.1097/01.sla.0000254368.65878.da] [Cited by in Crossref: 220] [Cited by in F6Publishing: 217] [Article Influence: 14.7] [Reference Citation Analysis]
200 Lee CW, Chan KM, Lee CF, Yu MC, Lee WC, Wu TJ, Chen MF. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg 2011;34:53-62. [PMID: 21723467 DOI: 10.1016/S1015-9584(11)60020-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
201 Gao S, Yang RJ, Dong JH. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. Chin J Cancer Res 2012;24:207-12. [PMID: 23359452 DOI: 10.1007/s11670-012-0207-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
202 Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011;80:373-381. [PMID: 21822028 DOI: 10.1159/000329040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
203 Vilana R, Llovet JM, Bianchi L, Sanchez M, Pagés M, Sala M, Gilabert R, Nicolau C, Garcia A, Ayuso C. Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound. 2003;31:119-128. [PMID: 12594796 DOI: 10.1002/jcu.10151] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
204 Fang AP, Long JA, Zhang YJ, Liu ZY, Li QJ, Zhang DM, Luo Y, Zhong RH, Zhou ZG, Xu YJ, Xu XJ, Ling WH, Chen MS, Zhu HL. Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival. Hepatology 2020;72:169-82. [PMID: 31677282 DOI: 10.1002/hep.31013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
205 Vauthey J, Lauwers GY. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest? Journal of Hepatology 2003;38:237-9. [DOI: 10.1016/s0168-8278(02)00407-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
206 Wiggermann P, Sieron D, Brosche C, Brauer T, Scheer F, Platzek I, Wawrzynek W, Stroszczynski C. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189-CR195. [PMID: 21455104 DOI: 10.12659/msm.881714] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
207 Tamai Y, Iwasa M, Kawasaki Y, Yoshizawa N, Ogura S, Sugimoto R, Eguchi A, Yamamoto N, Sugimoto K, Hasegawa H, Takei Y. Ratio between estimated glomerular filtration rates of creatinine and cystatin C predicts overall survival in patients with hepatocellular carcinoma. Hepatol Res 2019;49:153-63. [PMID: 30005446 DOI: 10.1111/hepr.13230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
208 Mazzaferro V, Roayaie S, Poon R, Majno PE. Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on “Surgical Misinterpretation” of the BCLC Staging System. Ann Surg. 2015;262:e17-e18. [PMID: 24368644 DOI: 10.1097/sla.0000000000000398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
209 Zitzelsberger T, Syha R, Grözinger G, Partovi S, Nikolaou K, Grosse U. Image quality of arterial phase and parenchymal blood volume (PBV) maps derived from C-arm computed tomography in the evaluation of transarterial chemoembolization. Cancer Imaging 2018;18:16. [PMID: 29720249 DOI: 10.1186/s40644-018-0151-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
210 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, Kim JY, Kim DY, Kim CM. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015;47:34-45. [PMID: 25381830 DOI: 10.4143/crt.2013.218] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
211 Liu Y, Yue H, Xu S, Wang F, Ma N, Li K, Qiao L, Wang J. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol. 2015;20:952-959. [PMID: 25712158 DOI: 10.1007/s10147-015-0796-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
212 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
213 Lee HS. Management of patients with hepatocellular carcinoma and extrahepatic metastasis. Dig Dis. 2011;29:333-338. [PMID: 21829026 DOI: 10.1159/000327572] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
214 Dasse KD, Lander MJ, Novelli PM. Chemoembolization With Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma. J Adv Pract Oncol 2016;7:764-78. [PMID: 29670812 DOI: 10.6004/jadpro.2016.7.7.8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
216 Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG; Italian Liver Cancer (ITA.LI.CA) group. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget 2018;9:17483-90. [PMID: 29707122 DOI: 10.18632/oncotarget.24756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
217 Choucair K, Kamran S, Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. Onco Targets Ther 2021;14:5521-32. [PMID: 35002257 DOI: 10.2147/OTT.S268309] [Reference Citation Analysis]
218 Shiba S, Shibuya K, Okamoto M, Okazaki S, Komatsu S, Kubota Y, Nakano T, Ohno T. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma. Radiat Oncol 2020;15:195. [PMID: 32795340 DOI: 10.1186/s13014-020-01634-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
219 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs Real World Outcomes 2020;7:141-9. [PMID: 32048238 DOI: 10.1007/s40801-020-00179-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
220 Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol. 2008;23:482-490. [PMID: 18086115 DOI: 10.1111/j.1440-1746.2007.05262.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
221 Kudo M. International comparison of treatment outcomes based on staging systems. Hepatol Res 2007;37 Suppl 2:S216-22. [PMID: 17877486 DOI: 10.1111/j.1872-034X.2007.00188.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
222 Verger E, Drion P, Meffre G, Bernard C, Duwez L, Lepareur N, Couturier O, Hindré F, Hustinx R, Lacoeuille F. 68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies. PLoS One 2016;11:e0164626. [PMID: 27741267 DOI: 10.1371/journal.pone.0164626] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
223 Hsieh Y, Limquiaco JL, Lin C, Chen W, Lin S. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol 2019;44:1141-51. [DOI: 10.1007/s00261-018-1831-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
224 Martí-Bonmatí L, Sanz-Requena R, de Gracia BP, Carot-Sierra JM. Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness. Expert Rev Gastroenterol Hepatol. 2012;6:711-716. [PMID: 23237256 DOI: 10.1586/egh.12.51] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
225 Thanos L, Mylona S, Nikita A, Ptohis N, Kelekis D. Long-Term Outcome of a Hepatocellular Carcinoma 7½ Years After Surgery and Repeated Radiofrequency Ablation: Case Report and Review of the Literature. Cardiovasc Intervent Radiol 2007;30:289-92. [DOI: 10.1007/s00270-006-0116-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
226 Bang H, Ha SY, Hwang SH, Park CK. Expression of PEG10 Is Associated with Poor Survival and Tumor Recurrence in Hepatocellular Carcinoma. Cancer Res Treat 2015;47:844-52. [PMID: 25687862 DOI: 10.4143/crt.2014.124] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
227 Pignata S, Gallo C, Daniele B, Elba S, Giorgio A, Capuano G, Adinolfi LE, De Sio I, Izzo F, Farinati F. Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP). Crit Rev Oncol Hematol. 2006;59:243-249. [PMID: 16916608 DOI: 10.1016/j.critrevonc.2006.01.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
228 Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210. [PMID: 25884354 DOI: 10.1186/s12885-015-1197-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
229 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [DOI: 10.1002/hep.23725] [Cited by in Crossref: 323] [Cited by in F6Publishing: 320] [Article Influence: 26.9] [Reference Citation Analysis]
230 Yopp AC, Mokdad A, Zhu H, Mansour JC, Balch GC, Choti MA, Singal AG. Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma. Ann Surg Oncol. 2015;22 Suppl 3:S1075-S1082. [PMID: 26245845 DOI: 10.1245/s10434-015-4786-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
231 Wich C, Agaimy A, Strobel D, Wissniowski TT, Hartmann A, Ocker M. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib. World J Gastroenterol 2010; 16(28): 3592-3596 [PMID: 20653070 DOI: 10.3748/wjg.v16.i28.3592] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
232 Huang J, Liu FC, Li L, Yuan SX, Yang Y, Jiang BG, Liu H, Pan ZY. Prognostic Nomogram for Hepatitis B Virus-related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection. Am J Clin Oncol 2020;43:20-7. [PMID: 31633514 DOI: 10.1097/COC.0000000000000619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
233 Boucher E, Forner A, Reig M, Bruix J. New drugs for the treatment of hepatocellular carcinoma. Liver Int 2009;29 Suppl 1:148-58. [PMID: 19207980 DOI: 10.1111/j.1478-3231.2008.01929.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
234 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
235 Lu L, Zheng P, Wu Z, Chen X. Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study. Front Oncol 2021;11:618937. [PMID: 34778022 DOI: 10.3389/fonc.2021.618937] [Reference Citation Analysis]
236 Kim Y, Park HC, Yoon SM, Kim TH, Lee J, Choi J, Yu JI, Park JH, Kim JH, Park JW, Seong J. Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02). Oncotarget 2017;8:94450-61. [PMID: 29212241 DOI: 10.18632/oncotarget.21775] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
237 Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8. [PMID: 25512453 DOI: 10.1200/JCO.2014.57.9151] [Cited by in Crossref: 802] [Cited by in F6Publishing: 406] [Article Influence: 100.3] [Reference Citation Analysis]
238 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
239 Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137:403-410. [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012] [Cited by in Crossref: 161] [Cited by in F6Publishing: 154] [Article Influence: 9.5] [Reference Citation Analysis]
240 Lee CH, Hsieh SY, Huang WH, Wang IK, Yen TH. Association between Ambient Particulate Matter 2.5 Exposure and Mortality in Patients with Hepatocellular Carcinoma. Int J Environ Res Public Health 2019;16:E2490. [PMID: 31336910 DOI: 10.3390/ijerph16142490] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
241 Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 2014;14:601. [PMID: 25139639 DOI: 10.1186/1471-2407-14-601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
242 Zheng BH, Liu LZ, Zhang ZZ, Shi JY, Dong LQ, Tian LY, Ding ZB, Ji Y, Rao SX, Zhou J, Fan J, Wang XY, Gao Q. Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer. 2018;18:1148. [PMID: 30463529 DOI: 10.1186/s12885-018-5024-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
243 Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN. Advances in the surgical management of liver malignancies. Cancer J 2004;10:74-87. [PMID: 15130267 DOI: 10.1097/00130404-200403000-00003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
244 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
245 Abou-alfa GK, Pawlik TM, Shindoh J, Vauthey J. Liver. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 287-93. [DOI: 10.1007/978-3-319-40618-3_22] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
246 Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39:2008-2023. [PMID: 31433891 DOI: 10.1111/liv.14220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
247 Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19(18): 2793-2798 [PMID: 23687416 DOI: 10.3748/wjg.v19.i18.2793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
248 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
249 Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, Tartaglione MT, Picciotto FP, Mattera S, De Luca M. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis. 2012;44:788-792. [PMID: 22579445 DOI: 10.1016/j.dld.2012.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
250 Wang T, Zhang XY, Lu X, Zhai B. Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. Technol Cancer Res Treat 2019;18:1533033818824338. [PMID: 30803390 DOI: 10.1177/1533033818824338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
251 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
252 Esnaola NF, Mirza N, Lauwers GY, Ikai I, Regimbeau JM, Belghiti J, Yamaoka Y, Curley SA, Ellis LM, Nagorney DM. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238:711-719. [PMID: 14578734 DOI: 10.1097/01.sla.0000094436.34556.ac] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
253 Pang Q, Bi JB, Wang ZX, Xu XS, Qu K, Miao RC, Chen W, Zhou YY, Liu C. Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. Onco Targets Ther 2016;9:2099-109. [PMID: 27110127 DOI: 10.2147/OTT.S101465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
254 Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology 2013;57:1426-35. [PMID: 22576353 DOI: 10.1002/hep.25832] [Cited by in Crossref: 189] [Cited by in F6Publishing: 177] [Article Influence: 21.0] [Reference Citation Analysis]
255 Lu XY, Xi T, Lau WY, Dong H, Xian ZH, Yu H, Zhu Z, Shen F, Wu MC, Cong WM. Pathobiological features of small hepatocellular carcinoma: correlation between tumor size and biological behavior. J Cancer Res Clin Oncol. 2011;137:567-575. [PMID: 20508947 DOI: 10.1007/s00432-010-0909-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
256 Díaz Sánchez A, Núñez Martínez O, Prieto Martín M, Beceiro Pedreño I, Calleja Kempin J, Santos Castro L, Muro de la Fuente A, Clemente Ricote G, Matilla Peña A. [Prognostic factors in patients with non-active treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2007;30:441-8. [PMID: 17949609 DOI: 10.1157/13110488] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19:659-666. [PMID: 28552299 DOI: 10.1016/j.hpb.2017.04.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
258 Zhuang L, Wen T, Xu M, Yang J, Wang W, Wu H, Zeng Y, Yan L, Wei Y, Li B. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. Arch Med Sci 2017;13:1383-93. [PMID: 29181069 DOI: 10.5114/aoms.2017.71066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
259 Sato N, Kenjo A, Kimura T, Okada R, Ishigame T, Kofunato Y, Shimura T, Abe K, Ohira H, Marubashi S. Prediction of major complications after hepatectomy using liver stiffness values determined by magnetic resonance elastography. Br J Surg 2018;105:1192-9. [PMID: 29683188 DOI: 10.1002/bjs.10831] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
260 Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, Kerr DJ. Hepatocellular carcinoma. Ann Oncol. 2001;12:161-172. [PMID: 11300318 DOI: 10.1023/a:1008370324827] [Cited by in Crossref: 78] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
261 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
262 Kinoshita A, Onoda H, Ueda K, Imai N, Iwaku A, Tanaka K, Fushiya N, Koike K, Nishino H, Tajiri H. Clinical characteristics and survival outcomes of super-elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatol Res 2016;46:E5-E14. [PMID: 25753133 DOI: 10.1111/hepr.12514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
263 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
264 Santambrogio R, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S, Opocher E. Recurrent hepatocellular carcinoma successfully treated with laparoscopic thermal ablation. Surg Endosc 2012;26:1108-15. [PMID: 22044972 DOI: 10.1007/s00464-011-2007-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
265 Zhang Y, Zhu K, Miao X, Hu X, Wang T. Identification of β -glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma is associated with resistance to chemotherapy drugs. Biomarkers 2016;21:249-56. [DOI: 10.3109/1354750x.2015.1134662] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
266 Yuan D, Wei YG, Li B, Yan LN, Wen TF, Zhao JC, Zeng Y, Chen KF. Evaluation outcomes of donors in living donor liver transplantation: a single-center analysis of 132 donors. Hepatobiliary Pancreat Dis Int 2011;10:480-8. [PMID: 21947721 DOI: 10.1016/s1499-3872(11)60082-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
267 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
268 Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, Mitsakis P, Silva-Monteiro M, Gnesin S, Lalonde MN, Duran R, Prior JO, Schaefer N. Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry. J Nucl Med 2017;58:1334-40. [PMID: 28082436 DOI: 10.2967/jnumed.116.184713] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
269 Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018;8:10434. [PMID: 29992975 DOI: 10.1038/s41598-018-28650-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
270 Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20(44): 16630-16638 [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
271 Mancuso A, Perricone G. Hepatocellular Carcinoma and Liver Transplantation: State of the Art. J Clin Transl Hepatol 2014;2:176-81. [PMID: 26357625 DOI: 10.14218/JCTH.2014.00013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
272 Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res 2009;28:142. [PMID: 19887008 DOI: 10.1186/1756-9966-28-142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
273 Van Deusen MA, Abdalla EK, Vauthey JN, Roh MS. Staging classifications for hepatocellular carcinoma. Expert Rev Mol Diagn 2005;5:377-83. [PMID: 15934814 DOI: 10.1586/14737159.5.3.377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
274 Lee YJ, Lee YR, Seo CG, Goh HG, Kim TH, Yim SY, Han NY, Lee JM, Choi HS, Kim ES, Keum B, An H, Park B, Seo YS, Yim HJ, Kim JH, Yu YD, Kim DS, Jeen YT, Chun HJ, Lee HS, Kim CD, Um SH. How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging? Cancers (Basel) 2020;12:E2589. [PMID: 32927918 DOI: 10.3390/cancers12092589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Du QC, Hu CL, Wang YY, Zhou Y. Comparison of the prognostic value of platelet-based prognostic models in patients with malignant hepatic tumors after TACE therapy. Acta Cir Bras 2019;34:e201900710. [PMID: 31531530 DOI: 10.1590/s0102-865020190070000010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
276 Franck M, Thon C, Schütte K, Malfertheiner P, Link A. Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function. World J Hepatol 2020; 12(11): 1031-1045 [PMID: 33312427 DOI: 10.4254/wjh.v12.i11.1031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
277 Vitale A, Navaglia F, Ramírez Morales R, Frigo AC, Basso D, D’Amico F, Zanus G, Bonsignore P, Farinati F, Burra P. Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies. PLoS One. 2011;6:e23093. [PMID: 21912636 DOI: 10.1371/journal.pone.0023093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
278 Huang YL, Wu JR, Fang M, Zhao HL, Liu ZM, Ye J, Huang LS, Zhu B. The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma. Medicine (Baltimore) 2019;98:e15090. [PMID: 30946366 DOI: 10.1097/MD.0000000000015090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
279 Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010;46:744-751. [PMID: 20060710 DOI: 10.1016/j.ejca.2009.12.018] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
280 Huo TI, Huang YH, Lee SD, Wu JC. Is there an ideal prognostic model for hepatocellular carcinoma? Gut 2005;54:1348. [PMID: 16099811 DOI: 10.1136/gut.2005.069468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
281 Ryder S. Predicting survival in early hepatocellular carcinoma. Gut 2005;54:328-9. [PMID: 15710977 DOI: 10.1136/gut.2004.052092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
282 Delis SG, Bakoyiannis A, Dervenis C, Tassopoulos N. Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. J Gastrointest Surg 2009;13:2268-75. [PMID: 19662460 DOI: 10.1007/s11605-009-0977-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
283 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: The best is yet to come. World J Radiol 2015; 7(10): 306-318 [PMID: 26516427 DOI: 10.4329/wjr.v7.i10.306] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
284 Lim C, Osseis M, Lahat E, Doussot A, Sotirov D, Hemery F, Lantéri-minet M, Feray C, Salloum C, Azoulay D. Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study. Surg Endosc 2019;33:811-20. [DOI: 10.1007/s00464-018-6347-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
285 Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012; 18(23): 2995-3003 [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
286 Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology. 2014;272:284-293. [PMID: 24708192 DOI: 10.1148/radiol.14131946] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
287 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Mahady SE, Charlton B, Fitzgerald P, Koorey DJ, Perry JF, Waugh RC, McCaughan GW, Strasser SI. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage? J Gastroenterol Hepatol 2010;25:1299-305. [PMID: 20594260 DOI: 10.1111/j.1440-1746.2010.06267.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
289 Zhang ZY, Zhang EL, Zhang BX, Chen XP, Zhang W. Treatment for hepatocellular carcinoma with tumor thrombosis in the hepatic vein or inferior vena cava: A comprehensive review. World J Gastrointest Surg 2021; 13(8): 796-805 [PMID: 34512903 DOI: 10.4240/wjgs.v13.i8.796] [Reference Citation Analysis]
290 Xin H, Liang D, Zhang M, Ren D, Chen H, Zhang H, Li S, Ding G, Zhang C, Ding Z, Wu L, Han W, Zhou W, Chen Y, Luo H, Wang Y, Zhang H, Liu S, Li N. The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. HPB (Oxford) 2021;23:1061-71. [PMID: 33309570 DOI: 10.1016/j.hpb.2020.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
291 Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther 2016;43:621-30. [PMID: 26784271 DOI: 10.1111/apt.13505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
292 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
293 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
294 Otto G, Pitton MB, Hoppe-Lotichius M, Weinmann A. Liver transplantation and BCLC classification: Limitations impede optimum treatment. Hepatobiliary Pancreat Dis Int 2021;20:6-12. [PMID: 33349607 DOI: 10.1016/j.hbpd.2020.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
295 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Dodson RM, He J, Pawlik TM. Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options. Future Oncology 2014;10:587-607. [DOI: 10.2217/fon.13.225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
297 Llovet JM, Bruix J. Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials. J Clin Oncol 2009;27:833-5. [PMID: 19139428 DOI: 10.1200/JCO.2008.19.1973] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
298 Sahu SK, Taneja S, Kalra N, Dhiman RK, Chawla YK, Duseja A, Singh V. Rupture of Hepatocellular Carcinoma: a Tale of 20 Cases from a Tertiary Care Center in Northern India. J Gastrointest Cancer 2019;50:596-600. [PMID: 29399732 DOI: 10.1007/s12029-018-0063-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
299 Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018;24:219-24. [PMID: 29792289 DOI: 10.5152/dir.2018.17528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
300 Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, Iacono C. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597-604. [PMID: 17970836 DOI: 10.1111/j.1572-0241.2007.01604.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis]
301 Li X, Dong M, Lin Q, Chen ZH, Ma XK, Xing YF, Wan XB, Wen JY, Wei L, Chen J, Wu XY. Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.Asia Pac J Clin Oncol. 2013;9:86-92. [PMID: 23279888 DOI: 10.1111/ajco.12050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
302 Steins M, Thomas M, Geißler M. Erlotinib. In: Martens UM, editor. Small Molecules in Oncology. Berlin: Springer Berlin Heidelberg; 2010. pp. 21-31. [DOI: 10.1007/978-3-642-01222-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
303 Notake T, Kobayashi A, Shinkawa H, Kawahara T, Shimizu A, Yokoyama T, Hasegawa K, Kokudo N, Matsuyama Y, Makuuchi M, Miyagawa SI. Nomogram predicting long-term survival after the diagnosis of intrahepatic recurrence of hepatocellular carcinoma following an initial liver resection. Int J Clin Oncol 2017;22:715-25. [PMID: 28303401 DOI: 10.1007/s10147-017-1114-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
304 Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, Lim YS, Lee HC, Chung YH, Lee YS. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806-814. [PMID: 19207681 DOI: 10.1111/j.1440-1746.2008.05728.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 95] [Article Influence: 7.5] [Reference Citation Analysis]
305 Benedetti Cacciaguerra A, Görgec B, Lanari J, Cipriani F, Russolillo N, Mocchegiani F, Zimmitti G, Alseidi A, Ruzzenente A, Edwin B, D'Hondt M, Besselink MG, Giuliante F, Fuks D, Rotellar F, López-Ben S, Ferrero A, Aldrighetti L, Cillo U, Vivarelli M, Abu Hilal M. Outcome of major hepatectomy in cirrhotic patients; does surgical approach matter? A propensity score matched analysis. J Hepatobiliary Pancreat Sci 2021. [PMID: 34855277 DOI: 10.1002/jhbp.1087] [Reference Citation Analysis]
306 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
307 Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B, Fresno-Forcelledo MF, Rodrigo L. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769-778. [PMID: 23742263 DOI: 10.1111/hepr.12180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
308 Wörns MA, Galle PR. HCC therapies--lessons learned. Nat Rev Gastroenterol Hepatol 2014;11:447-52. [PMID: 24492278 DOI: 10.1038/nrgastro.2014.10] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 12.3] [Reference Citation Analysis]
309 Takada H, Amemiya F, Yasumura T, Yoda H, Okuwaki T, Imagawa N, Shimamura N, Tanaka K, Kadokura M, Maekawa S, Enomoto N. Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. Sci Rep 2020;10:10186. [PMID: 32576956 DOI: 10.1038/s41598-020-67147-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Nam BH, Park JW, Jeong SH, Lee SS, Yu A, Kim BH, Kim WR. Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH). PLoS One 2015;10:e0138374. [PMID: 26488298 DOI: 10.1371/journal.pone.0138374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
311 Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology 2015;275:438-47. [PMID: 25531387 DOI: 10.1148/radiol.14141180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
312 Lin BZ, Lin TJ, Lin CL, Liao LY, Chang TA, Lu BJ, Chen KY. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. J Chin Med Assoc 2021;84:606-13. [PMID: 33871391 DOI: 10.1097/JCMA.0000000000000530] [Reference Citation Analysis]
313 Han X, Cheng W, Jing H, Zhang J, Tang L. Neuroepithelial Transforming Protein 1 Short Interfering RNA-Mediated Gene Silencing With Microbubble and Ultrasound Exposure Inhibits the Proliferation of Hepatic Carcinoma Cells In Vitro. Journal of Ultrasound in Medicine 2012;31:853-61. [DOI: 10.7863/jum.2012.31.6.853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
314 Lopez-Lopez V, Brusadin R, López-Conesa A, Capel A, Navarro-Barrios Á, Cayuela V, Lopez-Banet E, Garzón-Arana A, Parrilla-Paricio P, Robles-Campos R. Preoperative transarterial chemoembolization for laparoscopic liver resection in Child A cirrhotic patients with hepatocellular carcinoma. Langenbecks Arch Surg 2021;406:763-71. [PMID: 33411038 DOI: 10.1007/s00423-020-02056-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Sun L, Guan A, Liu M, Mao Y. Letter to the Editor: Comment on "HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk". Hepatology 2021;73:2613-4. [PMID: 33169424 DOI: 10.1002/hep.31621] [Reference Citation Analysis]
316 Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 2004;10:S91-7. [PMID: 14762847 DOI: 10.1002/lt.20043] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
317 Guo H, Wu T, Lu Q, Li M, Guo JY, Shen Y, Wu Z, Nan KJ, Lv Y, Zhang XF. Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages. Cancer Manag Res 2018;10:361-9. [PMID: 29503583 DOI: 10.2147/CMAR.S152707] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
318 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
319 Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Journal of Hepatology 2008;48:848-57. [DOI: 10.1016/j.jhep.2008.02.005] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
320 Yip B, Wantuck JM, Kim LH, Wong RJ, Ahmed A, Garcia G, Nguyen MH. Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci 2014;59:192-200. [PMID: 24282055 DOI: 10.1007/s10620-013-2948-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
321 Wu Y, Shen L, Qi H, Cao F, Chen S, Xie L, Huang T, Zhou D, Mo J, Fan W. Surveillance Strategy for Patients With BCLC Stage B Hepatocellular Carcinoma After Achieving Complete Remission: Data From the Real World. Front Oncol 2020;10:574804. [PMID: 33117712 DOI: 10.3389/fonc.2020.574804] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
323 Shen H, Li H, Zhou J. Circular RNA hsa_circ_0032683 inhibits the progression of hepatocellular carcinoma by sponging microRNA-338-5p. Bioengineered 2022;13:2321-35. [PMID: 35030979 DOI: 10.1080/21655979.2021.2024961] [Reference Citation Analysis]
324 Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650-2655. [PMID: 17304512 DOI: 10.1002/ijc.22616] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
325 Miura JT, Johnston FM, Tsai S, Eastwood D, Banerjee A, Christians KK, Turaga KK, Gamblin TC. Surgical resection versus ablation for hepatocellular carcinoma ≤ 3 cm: a population-based analysis. HPB (Oxford) 2015;17:896-901. [PMID: 26228076 DOI: 10.1111/hpb.12446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
326 Burgmans MC, van Erkel AR, Too CW, Coenraad M, Lo RH, Tan BS. Pilot study evaluating catheter-directed contrast-enhanced ultrasound compared to catheter-directed computed tomography arteriography as adjuncts to digital subtraction angiography to guide transarterial chemoembolization. Clin Radiol. 2014;69:1056-1061. [PMID: 25017449 DOI: 10.1016/j.crad.2014.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
327 Blumer T, Fofana I, Matter MS, Wang X, Montazeri H, Calabrese D, Coto-Llerena M, Boldanova T, Nuciforo S, Kancherla V, Tornillo L, Piscuoglio S, Wieland S, Terracciano LM, Ng CKY, Heim MH. Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. Hepatol Commun 2019;3:971-86. [PMID: 31334445 DOI: 10.1002/hep4.1365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
328 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
329 Luo KZ, Itamoto T, Amano H, Oshita A, Ushitora Y, Tanimoto Y, Ohdan H, Tashiro H, Asahara T. Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol 2008;43:369-77. [PMID: 18592155 DOI: 10.1007/s00535-008-2164-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
330 Zhang X, Bai Y, Xu L, Zhang B, Feng S, Xu L, Zhang H, Xu L, Yang P, Niu T, Zheng S, Liu J. Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. Hepatol Int 2019;13:715-25. [PMID: 31531761 DOI: 10.1007/s12072-019-09978-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
331 Bruix J, Llovet JM. Locoregional treatments for hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:611-622. [PMID: 10654923 DOI: 10.1053/bega.1999.0051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
332 Serenari M, Ratti F, Zanello M, Guglielmo N, Mocchegiani F, Di Benedetto F, Nardo B, Mazzaferro V, Cillo U, Massani M, Colledan M, Dalla Valle R, Cescon M, Vivarelli M, Colasanti M, Ettorre GM, Aldrighetti L, Jovine E. Minimally Invasive Stage 1 to Protect Against the Risk of Liver Failure: Results from the Hepatocellular Carcinoma Series of the Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Italian Registry. J Laparoendosc Adv Surg Tech A 2020;30:1082-9. [PMID: 32907480 DOI: 10.1089/lap.2020.0563] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
333 Hao F, Wang N, Wang X, Chen Y, Wang J. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma. Aging (Albany NY) 2021;13:18789-805. [PMID: 34285143 DOI: 10.18632/aging.203322] [Reference Citation Analysis]
334 Parikh ND, Scaglione S, Li Y, Powell C, Yerokun OA, Devlin P, Mumtaz S, Mittal S, Singal AG. A Comparison of Staging Systems for Hepatocellular Carcinoma in a Multicenter US Cohort. Clin Gastroenterol Hepatol. 2018;16:781-782. [PMID: 28987503 DOI: 10.1016/j.cgh.2017.10.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
335 D’Onofrio M, Ciaravino V, De Robertis R, Barbi E, Salvia R, Girelli R, Paiella S, Gasparini C, Cardobi N, Bassi C. Percutaneous ablation of pancreatic cancer. World J Gastroenterol 2016; 22(44): 9661-9673 [PMID: 27956791 DOI: 10.3748/wjg.v22.i44.9661] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
336 Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, Kim YS, Yim HJ, Um SH, Chung WJ, Hwang JS, Cho S, Eun JR. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2015;75:739-46. [DOI: 10.1007/s00280-015-2692-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
337 Omran M, Fouda M, Abdelwahab AO, Nabeel MM, Abdelaziz AO, Omran D, Shousha HI. P53 is a risk factor of de-novo hepatitis C-related hepatocellular carcinoma treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol 2022;34:220-6. [PMID: 33079785 DOI: 10.1097/MEG.0000000000001962] [Reference Citation Analysis]
338 Pang RWC, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RTP. Biology of Hepatocellular Carcinoma. Ann Surg Oncol 2008;15:962-71. [DOI: 10.1245/s10434-007-9730-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
339 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12003-12021 [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
340 Liu W, Wang K, Bao Q, Sun Y, Xing BC. Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma. World J Surg Oncol 2016;14:62. [PMID: 26936459 DOI: 10.1186/s12957-016-0811-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
341 Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-Radosavljevic M. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol. 2014;60:118-126. [PMID: 24012941 DOI: 10.1016/j.jhep.2013.08.022] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 7.9] [Reference Citation Analysis]
342 Ahn SJ, Park MS, Kim KA, Park JY, Kim I, Kang WJ, Lee SK, Kim MJ. 18F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One. 2013;8:e71571. [PMID: 23940769 DOI: 10.1371/journal.pone.0071571] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
343 Giannini E, Risso D, Botta F, Romagnoli P, Malfatti F, Fumagalli A, Testa E, Podestà E, Chiarbonello B, Polegato S, Testa R. Prognosis of hepatocellular carcinoma in anti-HCV positive cirrhotic patients: a single-centre comparison amongst four different staging systems. J Intern Med 2004;255:399-408. [PMID: 14871465 DOI: 10.1046/j.1365-2796.2003.01284.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
344 Yan L, Liang X, Huang H, Zhang G, Liu T, Zhang J, Chen Z, Zhang Z, Chen Y. S-Adenosylmethionine Affects Cell Cycle Pathways and Suppresses Proliferation in Liver Cells. J Cancer 2019;10:4368-79. [PMID: 31413757 DOI: 10.7150/jca.25422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
345 Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Munoz OE, O'Neill J, Nir I, Morris KT. Racial disparities in treatment and survival of hepatocellular carcinoma in native Americans and Hispanics. Am J Surg 2017;214:100-4. [PMID: 28624027 DOI: 10.1016/j.amjsurg.2016.09.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
346 Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K. Initial experience of transcatheter arterial chemoembolization during portal vein occlusion for unresectable hepatocellular carcinoma with marked arterioportal shunts. Eur Radiol. 2009;19:2016-2023. [PMID: 19238387 DOI: 10.1007/s00330-009-1349-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
347 Chang IS, Rhim H, Kim SH, Kim YS, Choi D, Park Y, Lim HK. Biloma formation after radiofrequency ablation of hepatocellular carcinoma: incidence, imaging features, and clinical significance. AJR Am J Roentgenol. 2010;195:1131-1136. [PMID: 20966318 DOI: 10.2214/ajr.09.3946] [Cited by in Crossref: 36] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
348 Cho CS. Prognostication systems as applied to primary and metastatic hepatic malignancies. Surg Oncol Clin N Am 2015;24:41-56. [PMID: 25444468 DOI: 10.1016/j.soc.2014.09.010] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
349 Kao WY, Su CW, Chiou YY, Chiu NC, Liu CA, Fang KC, Huo TI, Huang YH, Chang CC, Hou MC, Lin HC, Wu JC. Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency Ablation. Radiology. 2017;285:670-680. [PMID: 28562211 DOI: 10.1148/radiol.2017162382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
350 Hsu CY, Liu PH, Ho SY, Huang YH, Lee YH, Chiou YY, Hsieh TH, Fang T, Tsai YJ, Hou MC, Huo TI. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS One 2017;12:e0188031. [PMID: 29125877 DOI: 10.1371/journal.pone.0188031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
351 Koda M, Murawaki Y, Hirooka Y, Kitamoto M, Ono M, Sakaeda H, Joko K, Sato S, Tamaki K, Yamasaki T, Shibata H, Shimoe T, Matsuda T, Toshikuni N, Fujioka S, Ohmoto K, Nakamura S, Kariyama K, Aikata H, Kobayashi Y, Tsutsui A. Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients: Complications of RFA for HCC. Hepatology Research 2012;42:1058-64. [DOI: 10.1111/j.1872-034x.2012.01025.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
352 Cai BB, Shi KQ, Li P, Chen BC, Shi L, Johnson PJ, Lai P, Toyoda H, Zhou MT. A nomogram integrating hepatic reserve and tumor characteristics for hepatocellular carcinoma following curative liver resection. Clin Chim Acta 2018;485:187-94. [PMID: 29908940 DOI: 10.1016/j.cca.2018.06.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
353 Rich NE, Parikh ND, Singal AG. Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance. Semin Liver Dis 2017;37:296-304. [PMID: 29272892 DOI: 10.1055/s-0037-1608775] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
354 Chiang CL, Chan MKH, Yeung CSY, Ho CHM, Lee FAS, Lee VWY, Wong FCS, Blanck O. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma. Strahlenther Onkol 2019;195:254-64. [PMID: 30413833 DOI: 10.1007/s00066-018-1391-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
355 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
356 Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras (1992) 2013;59:514-24. [PMID: 24041910 DOI: 10.1016/j.ramb.2013.03.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
357 McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis. 2010;14:461-476. [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
358 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
359 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
360 Schiro BJ, Amour ES, Harnain C, Gandhi RT. Management of High Hepatopulmonary Shunts in the Setting of Y90 Radioembolization. Tech Vasc Interv Radiol 2019;22:58-62. [PMID: 31079711 DOI: 10.1053/j.tvir.2019.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Cai X, Chen Z, Chen J, Ma X, Bai M, Wang T, Chen X, Wu D, Wei L, Li X, Lin Q, Wen J, Ruan D, Lin Z, Dong M, Wu X. Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. J Cancer 2018;9:189-97. [PMID: 29290785 DOI: 10.7150/jca.21799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
362 Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. Radiat Oncol 2017;12:116. [PMID: 28701219 DOI: 10.1186/s13014-017-0851-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
363 Abdel-rahman O, Fouad M. Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review. Expert Review of Anticancer Therapy 2014;15:165-82. [DOI: 10.1586/14737140.2015.978295] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
364 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
365 Donadon M, Costa G, Cimino M, Procopio F, Fabbro DD, Palmisano A, Torzilli G. Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score. World J Surg. 2015;39:237-243. [PMID: 25217112 DOI: 10.1007/s00268-014-2786-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
366 Kapacee ZA, Mcnamara MG, de Liguori Carino N, Lamarca A, Valle JW, Hubner RA. Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare? European Journal of Surgical Oncology 2021;47:583-90. [DOI: 10.1016/j.ejso.2020.03.210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
367 Li L, Gou C, Li J, Achakzai R, Li X. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C. Hepatobiliary & Pancreatic Diseases International 2016;15:152-7. [DOI: 10.1016/s1499-3872(16)60070-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Shi HS, Wang S, Li MJ, Wu LQ. A Hepatocellular Carcinoma Patient with TSC1 Mutations Benefits from Treatment with Everolimus: A Case Report. Visc Med 2021;37:116-9. [PMID: 33981751 DOI: 10.1159/000505950] [Reference Citation Analysis]
369 Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017;19:18-30. [PMID: 28434945 DOI: 10.1016/j.ebiom.2017.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
370 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
371 Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285-1292. [PMID: 30171360 DOI: 10.1007/s00330-018-5692-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
372 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
373 Houseni M, Mahmoud MA, Saad S, ElHussiny F, Shihab M. Advanced intra-tumoural structural characterisation of hepatocellular carcinoma utilising FDG-PET/CT: a comparative study of radiomics and metabolic features in 3D and 2D. Pol J Radiol 2021;86:e64-73. [PMID: 33708274 DOI: 10.5114/pjr.2021.103239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
374 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. Journal of Hepatology 2017;67:173-83. [DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 76] [Article Influence: 13.8] [Reference Citation Analysis]
375 Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee SG. The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. J Gastrointest Surg. 2015;19:1281-1290. [PMID: 25956724 DOI: 10.1007/s11605-015-2849-5] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 10.6] [Reference Citation Analysis]
376 Shao YY, Lu LC, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems. Br J Cancer. 2012;107:1672-1677. [PMID: 23059748 DOI: 10.1038/bjc.2012.466] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
377 Cai QY, Jiang JH, Jin RM, Jin GZ, Jia NY. The clinical significance of lipopolysaccharide binding protein in hepatocellular carcinoma. Oncol Lett 2020;19:159-66. [PMID: 31897126 DOI: 10.3892/ol.2019.11119] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
378 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
379 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
380 Cidon EU. Systemic treatment of hepatocellular carcinoma: Past, present and future. World J Hepatol 2017; 9(18): 797-807 [PMID: 28706578 DOI: 10.4254/wjh.v9.i18.797] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
381 Choi JW, Chung JW, Cho YK, Kim YJ, Yoon J, Kim H, Jae HJ. Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors. Cardiovasc Intervent Radiol 2015;38:937-45. [DOI: 10.1007/s00270-014-1032-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
382 Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F. Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. JCO 2010;28:2220-6. [DOI: 10.1200/jco.2009.26.7765] [Cited by in Crossref: 126] [Cited by in F6Publishing: 68] [Article Influence: 10.5] [Reference Citation Analysis]
383 Li W, Yu J, Lian B, Sun H, Li J, Zhang M, Li L, Li Y, Liu Q, Xie L. Identifying prognostic features by bottom-up approach and correlating to drug repositioning. PLoS One 2015;10:e0118672. [PMID: 25738841 DOI: 10.1371/journal.pone.0118672] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
384 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
385 Shiraki T, Ishizuka M, Kubota K, Kato M, Matsumoto T, Mori S, Shimizu T, Aoki T. An elevated neutrophil-to-lymphocyte ratio predicts a poor postoperative survival in primary hepatocellular carcinoma patients with a normal preoperative serum level of alpha-fetoprotein. Surg Today. 2019;49:661-669. [PMID: 30806789 DOI: 10.1007/s00595-019-01781-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Chen HY, Chen YM, Wu J, Yang FC, Lv Z, Qian YG, Zheng SS. Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer. Onco Targets Ther 2017;10:803-10. [PMID: 28243116 DOI: 10.2147/OTT.S115035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
388 Alemi F, Kwon E, Chiu J, Aoki H, Stewart L, Corvera CU. Laparoscopic treatment of liver tumours using a two-needle probe bipolar radiofrequency ablation device. HPB (Oxford) 2011;13:656-64. [PMID: 21843267 DOI: 10.1111/j.1477-2574.2011.00347.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
389 Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O'Grady JG, Harrison PM, Heneghan MA. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology. 2008;48:863-870. [PMID: 18752332 DOI: 10.1002/hep.22432] [Cited by in Crossref: 123] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
390 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Caja L, Dituri F, Mancarella S, Caballero-Diaz D, Moustakas A, Giannelli G, Fabregat I. TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. Int J Mol Sci 2018;19:E1294. [PMID: 29701666 DOI: 10.3390/ijms19051294] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 25.0] [Reference Citation Analysis]
392 Iavarone M, Primignani M, Vavassori S, Sangiovanni A, La Mura V, Romeo R, Colombo M. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. United European Gastroenterol J 2016;4:363-70. [PMID: 27403302 DOI: 10.1177/2050640615615041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
393 Wang H, Qian Y, Wu M, Cong W. Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg 2020;24:2737-47. [DOI: 10.1007/s11605-019-04251-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
394 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
395 Wang W, Lv J, Chen N, Lou B, Mao W, Wang P, Chen Y. Dysregulated serum metabolites in staging of hepatocellular carcinoma. Clin Biochem 2018;61:7-11. [PMID: 30195484 DOI: 10.1016/j.clinbiochem.2018.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
396 Au KP, Chan SC, Chok KS, Chan AC, Cheung TT, Ng KK, Lo CM. Child-Pugh Parameters and Platelet Count as an Alternative to ICG Test for Assessing Liver Function for Major Hepatectomy. HPB Surg 2017;2017:2948030. [PMID: 28951631 DOI: 10.1155/2017/2948030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
397 Czauderna C, Schmidtmann I, Koch S, Pilz L, Heinrich S, Otto G, Mittler J, Lang H, Kloeckner R, Düber C, Sprinzl MF, Worns MA, Galle PR, Marquardt JU, Weinmann A. High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J 2021. [PMID: 33709539 DOI: 10.1177/2050640620972611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Lv S, Li Y, Ning H, Zhang M, Jia Q, Wang X. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis. Sci Rep 2021;11:386. [PMID: 33431945 DOI: 10.1038/s41598-020-79321-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
399 Weber S, Jarnagin W, Duffy A, O'reilly EM, Abou-alfa GK, Blumgart L. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2008. pp. 1569-94. [DOI: 10.1016/b978-0-443-06694-8.50088-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
400 Abdelmaksoud AH, Mandooh S, Nabeel MM, Elbaz TM, Shousha HI, Monier A, Elattar IA, Abdelaziz AO. Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients. Asian Pac J Cancer Prev 2017;18:183-8. [PMID: 28240515 DOI: 10.22034/APJCP.2017.18.1.183] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
401 Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010;22:205-11. [PMID: 20566428 DOI: 10.1179/joc.2010.22.3.205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
402 Baldan A, Marino D, De Giorgio M, Angonese C, Cillo U, D'alessandro A, Masotto A, Massani M, Mazzucco M, Miola E, Neri D, Paccagnella D, Pivetta G, Stellato A, Tommasi L, Tremolada F, Tufano A, Zanus G, Farinati F; ON BEHALF OF GENE – GRUPPO EPATOCARCINOMA NORD-EST1. Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. Aliment Pharmacol Ther 2006;24:1495-501. [DOI: 10.1111/j.1365-2036.2006.03136.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
403 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
404 Stremitzer S, Tamandl D, Kaczirek K, Maresch J, Abbasov B, Payer BA, Ferlitsch A, Gruenberger T. Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma. Br J Surg. 2011;98:1752-1758. [PMID: 22009385 DOI: 10.1002/bjs.7672] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
405 Morisco F, Guarino M, Valvano MR, Auriemma F, Farinati F, Giannini EG, Ciccarese F, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Benvengù L, Gasbarrini A, Svegliati Baroni G, Foschi FG, Biasini E, Masotto A, Virdone R, Marra F, Caporaso N, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int 2018;38:2028-39. [PMID: 29745475 DOI: 10.1111/liv.13877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
406 Herold C, Reck T, Fischler P, Ott R, Radespiel-troeger M, Ganslmayer M, Hohenberger W, Hahn EG, Schuppan D. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre: Prognosis of hepatocellular carcinoma. Liver 2002;22:23-8. [DOI: 10.1046/j.0106-9543.2001.01571.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
407 Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, Choti MA. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007;245:435-442. [PMID: 17435551 DOI: 10.1097/01.sla.0000250420.73854.ad] [Cited by in Crossref: 145] [Cited by in F6Publishing: 133] [Article Influence: 9.7] [Reference Citation Analysis]
408 Gao HJ, Xu L, Zhang YJ, Chen MS. Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review. Chin J Cancer 2014;33:259-64. [PMID: 24325788 DOI: 10.5732/cjc.013.10133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
409 Yoo BK, Emdad L, Gredler R, Fuller C, Dumur CI, Jones KH, Jackson-Cook C, Su ZZ, Chen D, Saxena UH, Hansen U, Fisher PB, Sarkar D. Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proc Natl Acad Sci U S A 2010;107:8357-62. [PMID: 20404171 DOI: 10.1073/pnas.1000374107] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
410 Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(16): 4933-4945 [PMID: 25945007 DOI: 10.3748/wjg.v21.i16.4933] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
411 Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. J Oncol Pract 2017;13:e197-206. [PMID: 28029300 DOI: 10.1200/JOP.2016.017814] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
412 Bai Y, Lian Y, Wu J, Chen S, Lai J, Zheng Y, Tian Y, Yan M, Wang Y. A Prognostic Scoring System for Predicting Overall Survival of Patients with the TNM 8th Edition Stage I and II Hepatocellular Carcinoma After Surgery: A Population-Based Study. Cancer Manag Res 2021;13:2131-42. [PMID: 33688256 DOI: 10.2147/CMAR.S289826] [Reference Citation Analysis]
413 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. Hepatol Res 2021. [PMID: 34799975 DOI: 10.1111/hepr.13734] [Reference Citation Analysis]
414 Itri JN, Raghavan K, Patel SB, Broder JC, Tierney S, Gray D, Burleson J, Macdonald S, Seidenwurm DJ. Developing Quality Measures for Diagnostic Radiologists: Part 2. Journal of the American College of Radiology 2018;15:1366-84. [DOI: 10.1016/j.jacr.2018.05.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
415 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
416 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
417 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
418 Simons JP, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. In-hospital mortality from liver resection for hepatocellular carcinoma: A simple risk score. Cancer 2010;116:1733-8. [DOI: 10.1002/cncr.24904] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
419 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
420 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
421 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
422 N’Kontchou G, Aout M, Laurent A, Nahon P, Ganne-Carrié N, Grando V, Baghad I, Roulot D, Trinchet JC, Sellier N. Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis. J Hepatol. 2012;56:160-166. [PMID: 21703186 DOI: 10.1016/j.jhep.2011.03.026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
423 Li D, Kang J, Golas BJ, Yeung VW, Madoff DC. Minimally invasive local therapies for liver cancer. Cancer Biol Med. 2014;11:217-236. [PMID: 25610708 DOI: 10.7497/j.issn.2095-3941.2014.04.001] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
424 Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 2004;40:667-676. [PMID: 15349906 DOI: 10.1002/hep.20375] [Cited by in Crossref: 599] [Cited by in F6Publishing: 547] [Article Influence: 33.3] [Reference Citation Analysis]
425 Nguyen MH, Keeffe EB. General management. Best Practice & Research Clinical Gastroenterology 2005;19:161-74. [DOI: 10.1016/j.bpg.2004.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
426 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
427 Takayasu K. Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective. Oncology 2011;81 Suppl 1:105-10. [PMID: 22212943 DOI: 10.1159/000333269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
428 Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour J. Assessment of the Hong Kong Liver Cancer Staging System in Europe. Liver Int 2016;36:911-7. [DOI: 10.1111/liv.13045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
429 Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y. Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. Oncotarget 2018;9:35394-407. [PMID: 30459932 DOI: 10.18632/oncotarget.26247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
430 Aghemo A, Colombo M. Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside. Semin Immunopathol 2013;35:111-20. [DOI: 10.1007/s00281-012-0330-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
431 Meng F, Zhen S, Song B. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity. APMIS 2017;125:743-51. [PMID: 28493520 DOI: 10.1111/apm.12704] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
432 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
433 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
434 Ariizumi S, Kotera Y, Takahashi Y, Katagiri S, Yamamoto M. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol. 2013;107:408-413. [PMID: 22903402 DOI: 10.1002/jso.23226] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
435 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
436 Parsons HM, Chu Q, Karlitz JJ, Stevens JL, Harlan LC. Adoption of Sorafenib for the Treatment of Advanced-Stage Hepatocellular Carcinoma in Oncology Practices in the United States. Liver Cancer 2017;6:216-26. [PMID: 29234628 DOI: 10.1159/000473862] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
437 Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160-167. [PMID: 27730805 DOI: 10.3857/roj.2016.01970] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
438 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
439 Rich NE, Phen S, Desai N, Mittal S, Yopp AC, Yang JD, Marrero JA, Iyengar P, Infante RE, Singal AG. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01036-3. [PMID: 34555519 DOI: 10.1016/j.cgh.2021.09.022] [Reference Citation Analysis]
440 Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA. Is Resection or Transplantation the ideal Treatment in Patients with Hepatocellular Carcinoma in Cirrhosis if Both Are Possible? A Systematic Review and Metaanalysis. Ann Surg Oncol 2014;21:3096-107. [DOI: 10.1245/s10434-014-3808-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
441 Zhang R, Lin X, Liu H, Ma M, Chen J, Chen J, Gao D, Cui J, Chen R. Activated hepatic stellate cells promote progression of post-heat residual hepatocellular carcinoma from autophagic survival to proliferation. International Journal of Hyperthermia 2019;36:252-62. [DOI: 10.1080/02656736.2018.1558459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
442 Ng KK, Vauthey J, Pawlik TM, Lauwers GY, Regimbeau J, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database. Ann Surg Oncol 2005;12:364-73. [DOI: 10.1245/aso.2005.06.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 81] [Article Influence: 9.8] [Reference Citation Analysis]
443 El Nakeeb A, Sultan AM, Salah T, El Hemaly M, Hamdy E, Salem A, Moneer A, Said R, AbuEleneen A, Abu Zeid M, Abdallah T, Abdel Wahab M. Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy. World J Gastroenterol 2013; 19(41): 7129-7137 [PMID: 24222957 DOI: 10.3748/wjg.v19.i41.7129] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
444 Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu’ L, Rapaccini G. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int. 2015;35:223-231. [PMID: 25074434 DOI: 10.1111/liv.12649] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
445 Girotra M, Soota K, Dhaliwal AS, Abraham RR, Garcia-Saenz-de-Sicilia M, Tharian B. Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? World J Gastrointest Endosc 2018; 10(2): 56-68 [PMID: 29467916 DOI: 10.4253/wjge.v10.i2.56] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
446 Patel P, Schutzer SE, Pyrsopoulos N. Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol 2016; 7(3): 242-255 [PMID: 27574562 DOI: 10.4291/wjgp.v7.i3.242] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
447 Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009;44 Suppl 19:119-21. [PMID: 19148805 DOI: 10.1007/s00535-008-2244-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 6.6] [Reference Citation Analysis]
448 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
449 Serenari M, Zanello M, Schadde E, Toschi E, Ratti F, Gringeri E, Masetti M, Cillo U, Aldrighetti L, Jovine E; ALPPS Italian Registry Group. Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012-2014. HPB (Oxford) 2016;18:419-27. [PMID: 27154805 DOI: 10.1016/j.hpb.2016.02.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 6.7] [Reference Citation Analysis]
450 Tang H, Lu W, Yang Z, Jiang K, Chen Y, Lu S, Dong J. Risk factors and long-term outcome for postoperative intra-abdominal infection after hepatectomy for hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e6795. [PMID: 28445320 DOI: 10.1097/MD.0000000000006795] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
451 Marrero J, Maluccio MA, McCurdy H, Abou-Alfa GK. Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma. Cancer Control 2014;21:5-16. [PMID: 24681845 DOI: 10.1177/1073274814021002s02] [Reference Citation Analysis]
452 Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103-109. [PMID: 11115830 DOI: 10.1136/gut.48.1.103] [Cited by in Crossref: 138] [Cited by in F6Publishing: 141] [Article Influence: 6.6] [Reference Citation Analysis]
453 Aggarwal M, Arain A, Jin Z. Systemic treatment for hepatocellular carcinoma. Chronic Dis Transl Med 2018;4:148-55. [PMID: 30276361 DOI: 10.1016/j.cdtm.2018.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
454 Imai K, Yamashita YI, Nakao Y, Matsumoto T, Kinoshita S, Yusa T, Kitano Y, Kaida T, Hayashi H, Baba H. Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function? Ann Surg Oncol 2021;28:854-62. [PMID: 32740735 DOI: 10.1245/s10434-020-08960-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
455 Kamachi S, Mizuta T, Otsuka T, Nakashita S, Ide Y, Miyoshi A, Kitahara K, Eguchi Y, Ozaki I, Anzai K. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res 2016;46:201-8. [PMID: 26223826 DOI: 10.1111/hepr.12562] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
456 Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, Teufel A, Jung EM, Stroszczynski C, Wiggermann P. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep 2017;7:43687. [PMID: 28266600 DOI: 10.1038/srep43687] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
457 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
458 Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
459 Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45:1630-1639. [PMID: 19157858 DOI: 10.1016/j.ejca.2008.12.025] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
460 Matsui O. Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization. Clin Drug Investig 2012;32 Suppl 2:3-13. [PMID: 22873623 DOI: 10.1007/BF03265492] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
461 Mazzucco W, Vitale F, Mazzola S, Amodio R, Zarcone M, Alba D, Marotta C, Cusimano R, Allemani C. Does access to care play a role in liver cancer survival? The ten-year (2006-2015) experience from a population-based cancer registry in Southern Italy. BMC Cancer 2021;21:307. [PMID: 33761907 DOI: 10.1186/s12885-021-07935-0] [Reference Citation Analysis]
462 Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, Li YW, Tang ZY. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-642. [PMID: 19387533 DOI: 10.1007/s00535-009-0050-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
463 Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC, Wu JC. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients. Medicine (Baltimore). 2015;94:e1929. [PMID: 26512620 DOI: 10.1097/md.0000000000001929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
464 Schütte K, Schulz C, Malfertheiner P. Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment. Gastrointest Tumors 2014;1:84-92. [PMID: 26672483 DOI: 10.1159/000362583] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
465 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
466 Liu TA, Jan YJ, Ko BS, Chen SC, Liang SM, Hung YL, Hsu C, Shen TL, Lee YM, Chen PF, Wang J, Shyue SK, Liou JY. Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. Am J Pathol 2011;179:2698-708. [PMID: 21967815 DOI: 10.1016/j.ajpath.2011.08.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
467 Revuelta-herrero JL, Giménez-manzorro A, Matilla-peña A, Herranz-alonso A, Sanjurjo-sáez M. Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice. J Clin Pharm Ther 2018;43:906-9. [DOI: 10.1111/jcpt.12727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
468 Sagir Kahraman A. Radiomics in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1165-8. [PMID: 32844349 DOI: 10.1007/s12029-020-00493-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, Castiglione A, Ciccone G, Rizzetto M. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. [PMID: 23263829 DOI: 10.1007/s12032-012-0345-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
470 Carr BI, Buch SC, Kondragunta V, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. J Gastroenterol Hepatol. 2008;23:1259-1266. [PMID: 18699979 DOI: 10.1111/j.1440-1746.2008.05487.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
471 Leal JN, Gonen M, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol 2015;26:1112-21. [PMID: 26038273 DOI: 10.1016/j.jvir.2015.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
472 Zhang L, Ge N, Chen Y, Xie X, Yin X, Gan Y, Zhang B, Zhang J, Chen R, Wang Y, Ye S, Ren Z. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0532-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
473 Demirtas CO, D'Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep 2021;3:100347. [PMID: 34505035 DOI: 10.1016/j.jhepr.2021.100347] [Reference Citation Analysis]
474 Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011;117:2478-2488. [PMID: 24048796 DOI: 10.1002/cncr.25791] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
475 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
476 Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel) 2020;12:E1862. [PMID: 32664319 DOI: 10.3390/cancers12071862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
477 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
478 Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatol Res 2019;50:137-43. [DOI: 10.1111/hepr.13416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
479 Wang H, Wu MC, Cong WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis. Hepatol Res 2019;49:344-54. [PMID: 30117236 DOI: 10.1111/hepr.13241] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
480 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, Falco L, Caporaso N. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Target Oncol. 2017;12:61-67. [PMID: 27503006 DOI: 10.1007/s11523-016-0454-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
481 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
482 Graf D, Vallböhmer D, Knoefel WT, Kröpil P, Antoch G, Sagir A, Häussinger D. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;25:430-437. [PMID: 24666568 DOI: 10.1016/j.ejim.2014.03.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
483 Sim HW, Knox J, Dawson LA. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surg Oncol Clin N Am 2017;26:647-66. [PMID: 28923223 DOI: 10.1016/j.soc.2017.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
484 Syha R, Grözinger G, Grosse U, Maurer M, Zender L, Horger M, Nikolaou K, Ketelsen D. C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads. Cancer Imaging. 2015;15:22. [PMID: 26715200 DOI: 10.1186/s40644-015-0057-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
485 Li X, Han QC, Yu C, Luo YC, Wang F, Sun XH, Gao YQ, Tan WF, Xia Q. C-C chemokine hepatocellular carcinoma motif ligand 5-deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment. J Dig Dis 2021;22:433-41. [PMID: 33978316 DOI: 10.1111/1751-2980.12997] [Reference Citation Analysis]
486 Zhang X, Qi X, Meng B, Liu C, Yu L, Wang B, Lv Y. Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: Comparison of five staging systems. European Journal of Surgical Oncology (EJSO) 2010;36:718-24. [DOI: 10.1016/j.ejso.2010.05.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
487 Hoshino T, Takagi H, Naganuma A, Koitabashi E, Uehara S, Sakamoto N, Kudo T, Sato K, Kakizaki S. Advanced hepatocellular carcinoma responds to MK615, a compound extract from the Japanese apricot “Prunus mume”. World J Hepatol 2013; 5(10): 596-600 [PMID: 24179621 DOI: 10.4254/wjh.v5.i10.596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
488 Furtado R, Crawford M, Sandroussi C. Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:2700-7. [DOI: 10.1245/s10434-014-3511-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
489 Song SK, Park MG, Park SK, Chung CW, Park Y. MicroRNAs associated with microvascular invasion in hepatocellular carcinoma and their prognostic impacts in patients undergoing hepatic resection. Oncol Lett 2019;18:6293-303. [PMID: 31788107 DOI: 10.3892/ol.2019.10987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
490 Mähringer‐kunz A, Wagner F, Hahn F, Weinmann A, Brodehl S, Schotten S, Hinrichs JB, Düber C, Galle PR, Pinto dos Santos D, Kloeckner R. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. Liver Int 2019;40:694-703. [DOI: 10.1111/liv.14380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
491 Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-e22. [PMID: 22047762 DOI: 10.1016/s1470-2045(11)70175-9.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
492 Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. Liver International 2009;29:443-8. [DOI: 10.1111/j.1478-3231.2008.01890.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
493 Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J 2016;22:365-72. [PMID: 27870678 DOI: 10.1097/PPO.0000000000000227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
494 Maida M, Orlando E, Cammà C, Cabibbo G. Staging systems of hepatocellular carcinoma: A review of literature. World J Gastroenterol 2014; 20(15): 4141-4150 [PMID: 24764652 DOI: 10.3748/wjg.v20.i15.4141] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
495 Ko BS, Lai IR, Chang TC, Liu TA, Chen SC, Wang J, Jan YJ, Liou JY. Involvement of 14-3-3γ overexpression in extrahepatic metastasis of hepatocellular carcinoma. Hum Pathol 2011;42:129-35. [PMID: 20870266 DOI: 10.1016/j.humpath.2010.01.028] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
496 Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014;9:e90929. [PMID: 24603710 DOI: 10.1371/journal.pone.0090929] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
497 Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci. 2011;31:637-641. [PMID: 22038353 DOI: 10.1007/s11596-011-0574-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
498 Marelli L, Shusang V, Buscombe JR, Cholongitas E, Stigliano R, Davies N, Tibballs J, Patch D, Meyer T, Burroughs AK. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med 2009;50:871-7. [PMID: 19443599 DOI: 10.2967/jnumed.108.060558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
499 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
500 Xu YX, Wang YB, Tan YL, Xi C, Xu XZ. Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis. Medicine (Baltimore). 2019;98:e14027. [PMID: 30633195 DOI: 10.1097/md.0000000000014027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
501 Pinter M, Wichlas M, Schmid K, Plank C, Müller C, Wrba F, Peck-radosavljevic M. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial: . European Journal of Gastroenterology & Hepatology 2008;20:1012-9. [DOI: 10.1097/meg.0b013e3283036740] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
502 Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology. 2019;69:1180-1192. [PMID: 30168613 DOI: 10.1002/hep.30244] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
503 Freedman J, Nilsson H, Jonas E. New horizons in ablation therapy for hepatocellular carcinoma. Hepat Oncol 2015;2:349-58. [PMID: 30191017 DOI: 10.2217/hep.15.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
504 Elgaml A, Elegezy M, El-Mesery M, El-Mowafy M. Natural variability in surface antigen and reverse transcriptase domain of hepatitis B virus in treatment-naïve chronic HBV-infected Egyptian patients. Virus Res 2021;302:198422. [PMID: 33836203 DOI: 10.1016/j.virusres.2021.198422] [Reference Citation Analysis]
505 Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H, Torimura T. Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers (Basel) 2021;13:4450. [PMID: 34503259 DOI: 10.3390/cancers13174450] [Reference Citation Analysis]
506 Sukowati CHC, El-Khobar KE, Tiribelli C. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World J Stem Cells 2021; 13(7): 795-824 [PMID: 34367478 DOI: 10.4252/wjsc.v13.i7.795] [Reference Citation Analysis]
507 Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, Jung DH, Park GC, Lee SG. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl 2017;23:781-90. [PMID: 28240808 DOI: 10.1002/lt.24752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
508 Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int 2015;35:591-600. [DOI: 10.1111/liv.12696] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
509 Ueno M, Morizane C, Ikeda M, Okusaka T, Ishii H, Furuse J. A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. Jpn J Clin Oncol. 2019;49:1073-1082. [PMID: 31822900 DOI: 10.1093/jjco/hyz150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
510 Jung HI, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ. Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor. Ann Surg Treat Res 2015;88:77-85. [PMID: 25692118 DOI: 10.4174/astr.2015.88.2.77] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
511 Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91:400-8. [PMID: 15048738 DOI: 10.1002/bjs.4554] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
512 Imada H, Kato H, Yasuda S, Yamada S, Yanagi T, Kishimoto R, Kandatsu S, Mizoe JE, Kamada T, Yokosuka O. Comparison of efficacy and toxicity of short-course carbon ion radiotherapy for hepatocellular carcinoma depending on their proximity to the porta hepatis. Radiother Oncol. 2010;96:231-235. [PMID: 20579756 DOI: 10.1016/j.radonc.2010.05.019] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
513 Chan SL, Yeo W. Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol. 2013;9:2-5. [PMID: 23418846 DOI: 10.1111/ajco.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
514 Lei Y, Yee LW, Zhou WP. Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization? Hepatobiliary Surg Nutr 2019;8:519-21. [PMID: 31673544 DOI: 10.21037/hbsn.2019.05.13] [Reference Citation Analysis]
515 Santambrogio R, Barabino M, Bruno S, Costa M, Ceretti AP, Angiolini MR, Zuin M, Meloni F, Opocher E. Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients. Surg Endosc. 2015;Epub ahead of print. [PMID: 26275555 DOI: 10.1007/s00464-015-4468-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
516 Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Schernthaner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Geschwind JF. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2017;15:746-755.e4. [PMID: 27847278 DOI: 10.1016/j.cgh.2016.10.036] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
517 Fassio E, Díaz S, Santa C, Elisa Reig M, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, Carlos de Souza F, Hernández N, Pinchuk L. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Annals of Hepatology 2010;9:63-9. [DOI: 10.1016/s1665-2681(19)31681-3] [Cited by in Crossref: 31] [Article Influence: 2.6] [Reference Citation Analysis]
518 Yang Y, Zhou Y, Zhou C, Ma X. Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00927-6. [PMID: 34862094 DOI: 10.1016/j.ejso.2021.11.120] [Reference Citation Analysis]
519 Lencioni R, Della Pina C, Cioni D, Crocetti L. Guidelines for the use of contrast-enhanced ultrasound in hepatocellular carcinoma. European Journal of Cancer Supplements 2008;6:1-8. [DOI: 10.1016/j.ejcsup.2008.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
520 Bae HM, Lee JH, Yoon JH, Kim YJ, Heo DS, Lee HS. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer. 2011;11:435. [PMID: 21985636 DOI: 10.1186/1471-2407-11-435] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
521 Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, Wang Q, Yee HT. Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. BMC Gastroenterol. 2012;12:64. [PMID: 22681852 DOI: 10.1186/1471-230x-12-64] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
522 Fujiyama S, Akuta N, Sezaki H, Kobayashi M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study. BMC Gastroenterol 2021;21:189. [PMID: 33892649 DOI: 10.1186/s12876-021-01770-0] [Reference Citation Analysis]
523 Wang Y, Ma L, Yuan Z, Zheng J, Li W. Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus: A retrospective study. PLoS One. 2018;13:e0201525. [PMID: 30063737 DOI: 10.1371/journal.pone.0201525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
524 Giangregorio F, Comparato G, Marinone MG, Di Stasi M, Sbolli G, Aragona G, Tansini P, Fornari F. Imaging detection of new HCCs in cirrhotic patients treated with different techniques: Comparison of conventional US, spiral CT, and 3-dimensional contrast-enhanced US with the Navigator technique (Nav 3D CEUS)(). J Ultrasound 2009;12:12-21. [PMID: 23397019 DOI: 10.1016/j.jus.2009.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
525 Xu M, Ma T, Shi S, Xing J, Xi Y. Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. Life (Basel) 2021;11:1312. [PMID: 34947843 DOI: 10.3390/life11121312] [Reference Citation Analysis]
526 Sonohara F, Nomoto S, Inokawa Y, Kanda M, Yamada S, Fujii T, Sugimoto H, Kodera Y. Serosal invasion strongly associated with recurrence after curative hepatic resection of hepatocellular carcinoma: a retrospective study of 214 consecutive cases. Medicine (Baltimore) 2015;94:e602. [PMID: 25738484 DOI: 10.1097/MD.0000000000000602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
527 Yi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, Ding Y, Lu G, Liu J, Ding H, Dai F, Tang X. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res 2014;26:112-8. [PMID: 24653633 DOI: 10.3978/j.issn.1000-9604.2014.02.09] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
528 Yin Y, Cheng JW, Chen FY, Chen XX, Zhang X, Huang A, Guo DZ, Wang YP, Cao Y, Fan J, Zhou J, Yang XR. A novel preoperative predictive model of 90-day mortality after liver resection for huge hepatocellular carcinoma. Ann Transl Med 2021;9:774. [PMID: 34268387 DOI: 10.21037/atm-20-7842] [Reference Citation Analysis]
529 Wan L, Dong DH, Wu XN, Ding HF, Lu Q, Tian Y, Zhang XF, Li W. Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B? Med Sci Monit 2020;26:e926797. [PMID: 33060558 DOI: 10.12659/MSM.926797] [Reference Citation Analysis]
530 Yılmaz A, Şimşek M, Hannarici Z, Büyükbayram ME, Bilici M, Tekin SB. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. Future Oncol 2021;17:4545-59. [PMID: 34431372 DOI: 10.2217/fon-2021-0457] [Reference Citation Analysis]
531 Lee V, Seong J, Yoon S, Wong T, Wang B, Zhang J, Chiang C, Ho P, Dawson L. Contrasting Some Differences in Managing Advanced Unresectable Hepatocellular Carcinoma Between the East and the West. Clinical Oncology 2019;31:560-9. [DOI: 10.1016/j.clon.2019.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
532 Kawasaki Y, Yang SJ, Choi GH, Han DH, Lee JH, Iino S, Sakoda M, Ueno S, Natsugoe S, Choi JS. New scoring system for resectable hepatocellular carcinoma with a maximum tumor size of ≤5 cm based on preoperative tumor factors. HPB (Oxford) 2019;21:1393-9. [PMID: 30922846 DOI: 10.1016/j.hpb.2019.02.018] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
533 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
534 Ward EM, Sherif AE, O'Neill S, Hughes M, Ireland H, Wigmore SJ, Adair A. Clinical Outcomes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Ann Transplant 2021;26:e931980. [PMID: 34326301 DOI: 10.12659/AOT.931980] [Reference Citation Analysis]
535 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Choi JI. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. Cancers (Basel) 2021;13:2975. [PMID: 34198589 DOI: 10.3390/cancers13122975] [Reference Citation Analysis]
536 Schwartz JD, Llovet JM. Molecular Targeting in Hepatocellular Carcinoma. In: Kaufman HL, Wadler S, Antman K, editors. Molecular Targeting in Oncology. Totowa: Humana Press; 2008. pp. 165-210. [DOI: 10.1007/978-1-59745-337-0_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
537 Parikh ND, Zhang P, Singal AG, Derstine BA, Krishnamurthy V, Barman P, Waljee AK, Su GL. Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Cancer Res Treat. 2018;50:530-537. [PMID: 28602057 DOI: 10.4143/crt.2017.156] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
538 Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun 2017;1:18-22. [PMID: 29404430 DOI: 10.1002/hep4.1014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
539 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2021;73 Suppl 1:115-127. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
540 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 25.6] [Reference Citation Analysis]
541 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
542 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
543 Hou W, Liu J, Chen P, Wang H, Ye BC, Qiang F. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett 2014;8:1249-54. [PMID: 25120700 DOI: 10.3892/ol.2014.2253] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
544 Huang LF, Xing X, Wu D, Xia Y, Li J, Wang K, Yan ZL, Wan XY, Shi LH, Yang T, Lau WY, Wu MC, Shen F. A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. Oncotarget 2016;7:25493-506. [PMID: 27027439 DOI: 10.18632/oncotarget.8333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
545 Welker M, Zangos S, Kriener S, Mönch C, Zeuzem S, Trojan J. Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma. J Gastrointest Canc 2010;41:149-52. [DOI: 10.1007/s12029-010-9146-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
546 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
547 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
548 Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol 2012;2012:421673. [PMID: 22655206 DOI: 10.5402/2012/421673] [Cited by in Crossref: 25] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
549 Rich NE, Yopp AC, Singal AG. Medical Management of Hepatocellular Carcinoma. JOP 2017;13:356-64. [DOI: 10.1200/jop.2017.022996] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 4.4] [Reference Citation Analysis]
550 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
551 Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700. e3. [PMID: 24583061 DOI: 10.1053/j.gastro.2014.02.032] [Cited by in Crossref: 339] [Cited by in F6Publishing: 329] [Article Influence: 42.4] [Reference Citation Analysis]
552 Li P, Zhai Y, Liu H, Lv FD, Li N, Ding HG. Diagnostic value of serum AFP alone or in combination with glypican 3, VEGF or IGF-II for patients with primary hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(25): 2702-2706 [DOI: 10.11569/wcjd.v18.i25.2702] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
553 Yang DS, Park S, Rim CH, Yoon WS, Shin IS, Lee HA. Salvage External Beam Radiotherapy after Incomplete Transarterial Chemoembolization for Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Medicina (Kaunas) 2021;57:1000. [PMID: 34684036 DOI: 10.3390/medicina57101000] [Reference Citation Analysis]
554 Huo TI, Huang YH, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009;29:767-73. [PMID: 19018974 DOI: 10.1111/j.1478-3231.2008.01908.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
555 Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Gores GJ, Feng Z, Marrero JA, Roberts LR. Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92. [PMID: 28258053 DOI: 10.1158/1055-9965.EPI-16-0747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
556 Yoon JS, Sinn DH, Lee JH, Kim HY, Lee CH, Kim SW, Lee HY, Nam JY, Chang Y, Lee YB, Cho EJ, Yu SJ, Kim HC, Chung JW, Kim YJ, Yoon JH. Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study. Cancers (Basel) 2019;11:E1721. [PMID: 31689972 DOI: 10.3390/cancers11111721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
557 Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592-600. [PMID: 19191771 DOI: 10.1111/j.1600-6143.2008.02516.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 116] [Article Influence: 8.9] [Reference Citation Analysis]
558 Brunello F, Cantamessa A, Gaia S, Carucci P, Rolle E, Castiglione A, Ciccone G, Rizzetto M. Radiofrequency ablation: technical and clinical long-term outcomes for single hepatocellular carcinoma up to 30 mm. Eur J Gastroenterol Hepatol. 2013;25:842-849. [PMID: 23442417 DOI: 10.1097/meg.0b013e32835ee5f1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
559 Yang XY, Wu B, Ma SL, Yin L, Wu MC, Li AJ. Decreased Expression of ZWINT is Associated With Poor Prognosis in Patients With HCC After Surgery. Technol Cancer Res Treat 2018;17:1533033818794190. [PMID: 30198401 DOI: 10.1177/1533033818794190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
560 Ratti F, Cipriani F, Fiorentini G, Catena M, Paganelli M, Aldrighetti L. Reappraisal of the advantages of laparoscopic liver resection for intermediate hepatocellular carcinoma within a stage migration perspective: Propensity score analysis of the differential benefit. J Hepatobiliary Pancreat Sci 2020;27:510-21. [PMID: 32189450 DOI: 10.1002/jhbp.736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
561 Yuan Z, Wang Y, Hu C, Gao W, Zheng J, Li W. Efficacy of Percutaneous Thermal Ablation Combined With Transarterial Embolization for Recurrent Hepatocellular Carcinoma After Hepatectomy and a Prognostic Nomogram to Predict Survival. Technol Cancer Res Treat 2018;17:1533033818801362. [PMID: 30244651 DOI: 10.1177/1533033818801362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
562 Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 2005;25:367-379. [PMID: 15780063 DOI: 10.1111/j.1478-3231.2005.01033.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
563 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
564 Shimizu T, Ishizuka M, Suzuki T, Tanaka G, Park KH, Matsumoto T, Shiraki T, Sakuraoka Y, Kato M, Aoki T, Kubota K. The preoperative globulin-to-albumin ratio, a novel inflammation-based prognostic system, predicts survival after potentially curative liver resection for patients with hepatocellular carcinoma. J Surg Oncol 2017;116:1166-75. [PMID: 28853157 DOI: 10.1002/jso.24772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
565 Ekinci O, Baran B, Ormeci AC, Soyer OM, Gokturk S, Evirgen S, Poyanli A, Gulluoglu M, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma. World J Hepatol 2018; 10(1): 51-61 [PMID: 29399278 DOI: 10.4254/wjh.v10.i1.51] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
566 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
567 Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R. Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg 2010;34:2146-54. [PMID: 20411387 DOI: 10.1007/s00268-010-0583-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
568 Zhang YL, Nie CH, Chen F, Zhou TY, Zhou GH, Zhu TY, Chen SQ, Chen XH, Wang HL, Wang BQ, Yu ZN, Jing L, He ZM, Sun JH. Adjuvant Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma After Hepatectomy. Front Oncol 2020;10:1754. [PMID: 32984060 DOI: 10.3389/fonc.2020.01754] [Reference Citation Analysis]
569 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
570 Dituri F, Serio G, Filannino D, Mascolo A, Sacco R, Villa E, Giannelli G. Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. Cancer Lett. 2014;353:264-271. [PMID: 25088578 DOI: 10.1016/j.canlet.2014.07.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
571 Parikh ND, Singal AG. The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. PLoS Med 2016;13:e1002005. [PMID: 27116028 DOI: 10.1371/journal.pmed.1002005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
572 Ouedraogo W, Tran-Van Nhieu J, Baranes L, Lin SJ, Decaens T, Laurent A, Djabbari M, Pigneur F, Duvoux C, Kobeiter H. [Evaluation of noninvasive diagnostic criteria for hepatocellular carcinoma on pretransplant MRI (2010): correlation between MR imaging features and histological features on liver specimen]. J Radiol. 2011;92:688-700. [PMID: 21819911 DOI: 10.1016/j.jradio.2011.03.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
573 Huang Z, Liang B, Xiong M, Dong K, Zhang Z, Zhang E, Li C, Chen X. Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. Surgery 2016;159:621-31. [DOI: 10.1016/j.surg.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
574 Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ 2020;8:e8497. [PMID: 32117619 DOI: 10.7717/peerj.8497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
575 García-valdecasas J, Fuster J, Charco R, Bombuy E, Fondevila C, Navasa M, Rodríguez-laiz G, Ferrer J, Amador M, Llovet J, Forns X, Rimola A. Trasplante hepático de donante vivo en adultos. Análisis de los 30 primeros casos. Gastroenterología y Hepatología 2003;26:525-30. [DOI: 10.1016/s0210-5705(03)70406-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
576 Daniele B, Annunziata M, Barletta E, Tinessa V, Di Maio M. Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma. Hepatology Research 2007;37:S206-9. [DOI: 10.1111/j.1872-034x.2007.00186.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
577 Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center. J Gastrointest Cancer 2018;49:463-9. [PMID: 28710606 DOI: 10.1007/s12029-017-9990-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
578 Ishikawa T. Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(37): 6127-6130 [PMID: 24115808 DOI: 10.3748/wjg.v19.i37.6127] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
579 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
580 Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008;47:1557-66. [PMID: 18318443 DOI: 10.1002/hep.22201] [Cited by in Crossref: 187] [Cited by in F6Publishing: 183] [Article Influence: 13.4] [Reference Citation Analysis]
581 Colombo M. Screening for Cancer in Viral Hepatitis. Clinics in Liver Disease 2001;5:109-22. [DOI: 10.1016/s1089-3261(05)70156-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
582 Bahng S, Yoo BC, Paik SW, Koh KC, Lee KT, Lee JK, Lee JH, Choi MS, Lee KH. Photodynamic therapy for bile duct invasion of hepatocellular carcinoma. Photochem Photobiol Sci 2013;12:439-45. [DOI: 10.1039/c2pp25265a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
583 Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652-659. [PMID: 11323504 DOI: 10.1097/00000658-200105000-00009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 11.5] [Reference Citation Analysis]
584 Gao Q, Wang X, Qiu S, Zhou J, Shi Y, Zhang B, Fan J. Tumor stroma reaction-related gene signature predicts clinical outcome in human hepatocellular carcinoma. Cancer Science 2011;102:1522-31. [DOI: 10.1111/j.1349-7006.2011.01981.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
585 Torzilli G, Donadon M, Belghiti J, Kokudo N, Takayama T, Ferrero A, Nuzzo G, Vauthey J, Choti MA, De Santibanes E, Makuuchi M. Predicting Individual Survival After Hepatectomy for Hepatocellular Carcinoma: a Novel Nomogram from the “HCC East & West Study Group”. J Gastrointest Surg 2016;20:1154-62. [DOI: 10.1007/s11605-016-3132-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
586 Xing H, Zhang WG, Cescon M, Liang L, Li C, Wang MD, Wu H, Lau WY, Zhou YH, Gu WM, Wang H, Chen TH, Zeng YY, Schwartz M, Pawlik TM, Serenari M, Shen F, Wu MC, Yang T. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford) 2020;22:677-89. [PMID: 31607637 DOI: 10.1016/j.hpb.2019.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
587 Yin XY, Xie XY, Lu MD, Kuang M, Liu GJ, Xu ZF, Xu HX, Wang Z. Percutaneous ablative therapies of recurrent hepatocellular carcinoma after hepatectomy: proposal of a prognostic model. Ann Surg Oncol. 2012;19:4300-4306. [PMID: 22766980 DOI: 10.1245/s10434-012-2433-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
588 Ariizumi S, Katagiri S, Katsuragawa H, Kotera Y, Yamamoto M. Sectionectomy Is Suitable for Patients with T2 Hepatocellular Carcinoma according to the Modified International Union against Cancer TNM Classification. Dig Surg 2007;24:342-8. [DOI: 10.1159/000107714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
589 Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015;38:352-60. [PMID: 25373796 DOI: 10.1007/s00270-014-1012-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
590 Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches. Hepatol Int. 2013;7:805-812. [PMID: 26201917 DOI: 10.1007/s12072-013-9454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
591 Xu P, Chen YJ, Chen H, Zhu XY, Song HF, Cao LJ, Wang XF. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver. 2014;8:186-195. [PMID: 24672661 DOI: 10.5009/gnl.2014.8.2.186] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
592 Wang T, Lu XJ, Chi JC, Ding M, Zhang Y, Tang XY, Li P, Zhang L, Zhang XY, Zhai B. Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. Sci Rep 2016;6:32728. [PMID: 27620527 DOI: 10.1038/srep32728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
593 Huang MD, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, Yin L, Zhang EB, De W, Shu YQ. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50. [PMID: 25966845 DOI: 10.1186/s13045-015-0146-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 64] [Article Influence: 3.7] [Reference Citation Analysis]
594 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
595 Borzio M, Colloredo G, Pioltelli P, Quagliuolo M. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis. 2007;39:1011-1017. [PMID: 17936698 DOI: 10.1016/j.dld.2007.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
596 Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation. 2014;98:100-106. [PMID: 24503764 DOI: 10.1097/01.tp.0000441090.39840.b0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
597 He W, Zeng Q, Zheng Y, Chen M, Shen J, Qiu J, Zou R, Liao Y, Li Q, Wu X, Li B, Yuan Y. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer. 2015;15:263. [PMID: 25886495 DOI: 10.1186/s12885-015-1280-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
598 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
599 Hyeon J, Ahn S, Park CK. CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol. 2013;47:9-15. [PMID: 23482400 DOI: 10.4132/koreanjpathol.2013.47.1.9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
600 Freeman RB. Liver allocation for HCC: A moving target. Liver Transpl 2004;10:49-51. [DOI: 10.1002/lt.20027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
601 Lin WR, Hsu CW, Yeh CS, Chen YC, Chang ML, Liang KH, Lin CC, Chu YD, Yeh CT. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2018;14:e54-63. [PMID: 28695683 DOI: 10.1111/ajco.12745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
602 Ferre-aracil C, Lledó J, Aguilera L, Garcia-paredes A, Rodríguez-santiago E, Graus J, García-gonzález M, Nuño J, López-buenadicha A, López-hervás P, Rodríguez-gandía M, Gea F, Albillos A. Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation. Digestive and Liver Disease 2018;50:1345-50. [DOI: 10.1016/j.dld.2018.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
603 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
604 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
605 Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol. 2012;18:18-22. [PMID: 22249087 DOI: 10.4103/1319-3767.91731] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
606 Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg. 2005;9:1207-1215; discussion 1215. [PMID: 16332475 DOI: 10.1016/j.gassur.2005.09.008] [Cited by in Crossref: 170] [Cited by in F6Publishing: 140] [Article Influence: 10.6] [Reference Citation Analysis]
607 Masaki T, Morishita A, Kurokohchi K, Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy 2014;6:1377-84. [DOI: 10.1586/14737140.6.10.1377] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
608 Nebbia G, Zhang Q, Arefan D, Zhao X, Wu S. Pre-operative Microvascular Invasion Prediction Using Multi-parametric Liver MRI Radiomics.J Digit Imaging. 2020;33:1376-1386. [PMID: 32495126 DOI: 10.1007/s10278-020-00353-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
609 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, Chi R, Zhang T, Wang L, Shen F, Wang D. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. Diabetes Res Clin Pract 2020;169:108375. [PMID: 32827592 DOI: 10.1016/j.diabres.2020.108375] [Reference Citation Analysis]
610 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
611 Li Q, Zhu LZ, Yang RJ, Zhu X. Cytotoxic activity of anticancer drugs on hepatocellular carcinoma cells in hypoxic-hyponutritional culture. Int Surg 2014;99:745-52. [PMID: 25437582 DOI: 10.9738/INTSURG-D-14-00073.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
612 Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 267] [Article Influence: 18.4] [Reference Citation Analysis]
613 Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014;86:63-71. [PMID: 24401634 DOI: 10.1159/000356573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Hucke F, Pinter M, Graziadei I, Bota S, Vogel W, Müller C, Heinzl H, Waneck F, Trauner M, Peck-radosavljevic M, Sieghart W. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. Journal of Hepatology 2014;61:1287-96. [DOI: 10.1016/j.jhep.2014.07.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 10.0] [Reference Citation Analysis]
615 Takakusagi S, Takagi H, Shibuya K, Kosone T, Sato K, Kakizaki S, Ohno T, Uraoka T. Two elder cases of hepatocellular carcinoma adjacent to intrahepatic vessels successfully treated by carbon ion radiotherapy. Clin J Gastroenterol 2020;13:920-6. [PMID: 32529487 DOI: 10.1007/s12328-020-01151-2] [Reference Citation Analysis]
616 Bennink RJ, Cieslak KP, van Delden OM, van Lienden KP, Klümpen HJ, Jansen PL, van Gulik TM. Monitoring of Total and Regional Liver Function after SIRT. Front Oncol 2014;4:152. [PMID: 24982851 DOI: 10.3389/fonc.2014.00152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
617 Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess 2010;14:17-21. [DOI: 10.3310/hta14suppl1-03] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
618 Masuzaki R, Yoshida H, Tateishi R, Omata M. Staging systems: is there a surgical staging and a medical one?: Hepatologist's perspective. Journal of Hepato-Biliary-Pancreatic Sciences 2010;17:440-2. [DOI: 10.1007/s00534-009-0240-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
619 Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2008;66:200-7. [DOI: 10.1016/j.critrevonc.2008.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
620 Ho SY, Liu PH, Hsu CY, Chiou YY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Prognostic Performance of Ten Liver Function Models in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Sci Rep. 2018;8:843. [PMID: 29339752 DOI: 10.1038/s41598-018-19251-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
621 Kikuchi LO, Paranaguá-vezozzo DC, Chagas AL, Mello ES, Alves VA, Farias AQ, Pietrobon R, Carrilho FJ. Nodules Less Than 20 mm and Vascular Invasion are Predictors of Survival in Small Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2009;43:191-5. [DOI: 10.1097/mcg.0b013e31817ff199] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
622 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. Hepatol Res. 2015;Aug 29; Epub ahead of print. [PMID: 26331402 DOI: 10.1111/hepr.12583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
623 Ito K, Takemura N, Inagaki F, Mihara F, Kokudo N. Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. Glob Health Med. 2020;2:282-291. [PMID: 33330822 DOI: 10.35772/ghm.2020.01066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
624 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
625 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
626 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
627 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
628 Moore A, Cohen-Naftaly M, Benjaminov O, Braun M, Issachar A, Mor E, Tovar A, Sarfaty M, Gordon N, Stemmer SM. Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer 2016;7:883-9. [PMID: 27313777 DOI: 10.7150/jca.14721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
629 Voron T, Tselikas L, Pietrasz D, Pigneur F, Laurent A, Compagnon P, Salloum C, Luciani A, Azoulay D. Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma. Ann Surg 2015;261:1173-83. [PMID: 24950264 DOI: 10.1097/SLA.0000000000000743] [Cited by in Crossref: 174] [Cited by in F6Publishing: 85] [Article Influence: 29.0] [Reference Citation Analysis]
630 Merchante N, Merino E, Rodríguez-arrondo F, Tural C, Muñoz J, Delgado-fernández M, Jover F, Galindo MJ, Rivero A, López-aldeguer J, Aguirrebengoa K, Romero-palacios A, Martínez E, Pineda JA. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. AIDS 2014;28:41-7. [DOI: 10.1097/qad.0000000000000005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
631 Chicco D, Oneto L. Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma. Health Informatics J 2021;27:1460458220984205. [PMID: 33504243 DOI: 10.1177/1460458220984205] [Reference Citation Analysis]
632 Zhu Q, Yuan B, Qiao G, Yan J, Li Y, Duan R, Yan Y. Prognostic factors for survival after hepatic resection of early hepatocellular carcinoma in HBV-related cirrhotic patients. Clinics and Research in Hepatology and Gastroenterology 2016;40:418-27. [DOI: 10.1016/j.clinre.2015.12.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
633 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
634 Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013;58:2721-2728. [PMID: 23703450 DOI: 10.1007/s10620-013-2716-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
635 Romero Gutiérrez M, Ruano Díaz L, Muñoz López D, Artaza Varasa T, González de Frutos C, Sánchez Ruano JJ, de la Cruz Pérez G, Gómez Rodríguez R. [Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice]. Gastroenterol Hepatol 2015;38:54-61. [PMID: 25499846 DOI: 10.1016/j.gastrohep.2014.11.002] [Reference Citation Analysis]
636 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
637 Zhao Z, Zhu Y, Ni X, Lin J, Li H, Zheng L, Zhang C, Qi X, Huo H, Lou X, Fan Q, Bao Y, Luo M. Serum GGT/ALT ratio predicts vascular invasion in HBV-related HCC. Cancer Cell Int 2021;21:517. [PMID: 34583704 DOI: 10.1186/s12935-021-02214-1] [Reference Citation Analysis]
638 Paul S, Dhamija E, Gamanagatti S, Sreenivas V, Yadav D, Jain S, Shalimar, Acharya S. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography. Diagnostic and Interventional Imaging 2017;98:253-60. [DOI: 10.1016/j.diii.2016.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
639 Liu PH, Hsu CY, Hsia CY, Lee YH, Chiou YY, Huang YH, Lee FY, Lin HC, Hou MC, Huo TI. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol. 2017;32:879-886. [PMID: 27696519 DOI: 10.1111/jgh.13608] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
640 Lo CH, Liu MY, Lee MS, Yang JF, Jen YM, Lin CS, Chao HL, Shen PC, Huang WY. Comparison Between Child-Turcotte-Pugh and Albumin-Bilirubin Scores in Assessing the Prognosis of Hepatocellular Carcinoma After Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;99:145-152. [PMID: 28816140 DOI: 10.1016/j.ijrobp.2017.04.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
641 Kim JU, Cox IJ, Taylor-Robinson SD. The Quest for Relevant Hepatocellular Carcinoma Biomarkers. Cell Mol Gastroenterol Hepatol 2017;4:283-4. [PMID: 28795124 DOI: 10.1016/j.jcmgh.2017.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
642 Chan KS, Low JK, Shelat VG. Associated liver partition and portal vein ligation for staged hepatectomy: a review. Transl Gastroenterol Hepatol 2020;5:37. [PMID: 32632388 DOI: 10.21037/tgh.2019.12.01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
643 Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, Huang WY. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793. [PMID: 28545098 DOI: 10.1371/journal.pone.0177793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
644 Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, Xiang BD, Wu FX, Ma L, Li LQ, Ye HH. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med 2016;12:3813-9. [PMID: 28105115 DOI: 10.3892/etm.2016.3810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
645 Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol. 2017;2:106. [PMID: 29354763 DOI: 10.21037/tgh.2017.11.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
646 Vitale A, Gringeri E, Valmasoni M, D'Amico F, Carraro A, Pauletto A, D'Amico FJ, Polacco M, D'Amico DF, Cillo U. Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience. Transplant Proc 2007;39:1892-4. [PMID: 17692645 DOI: 10.1016/j.transproceed.2007.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
647 Kamran AU, Liu Y, Li FE, Liu S, Wu JL, Zhang YW. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study. Medicine (Baltimore) 2015;94:e2154. [PMID: 26717358 DOI: 10.1097/MD.0000000000002154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
648 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int 2020;40:968-76. [DOI: 10.1111/liv.14405] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
649 Guerrero García A, González-Huix F, Levy MJ, García de Paredes AG, Vázquez-Sequeiros E. Ablative therapy in pancreatic cystic lesions. Gastroenterol Hepatol 2019;42:43-50. [PMID: 30131274 DOI: 10.1016/j.gastrohep.2018.07.004] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
650 Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, Springer F, Claussen CD, Brechtel K. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. Eur J Gastroenterol Hepatol 2012;24:1325-32. [PMID: 22872074 DOI: 10.1097/MEG.0b013e32835724bc] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
651 Omran MM, Farid K, Omar MA, Emran TM, El-Taweel FM, Tabll AA. A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma. Ann Hepatol 2020;19:179-85. [PMID: 31648804 DOI: 10.1016/j.aohep.2019.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
652 Khor AY, Toh Y, Allen JC, Ng DC, Kao YH, Zhu G, Choo SP, Lo RH, Tay KH, Teo JY, Goh BK, Burgmans MC, Irani FG, Goh AS, Chow PK. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatol Int 2014;8:395-404. [PMID: 26202641 DOI: 10.1007/s12072-014-9533-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
653 Jing CY, Fu YP, Zheng SS, Yi Y, Shen HJ, Huang JL, Xu X, Lin JJ, Zhou J, Fan J, Ren ZG, Qiu SJ, Zhang BH. Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection. Medicine (Baltimore) 2017;96:e6140. [PMID: 28296727 DOI: 10.1097/MD.0000000000006140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
654 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
655 Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000;6:s11-5. [DOI: 10.1053/jlts.2000.18684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
656 Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006; 12(42): 6771-6778 [PMID: 17106924 DOI: 10.3748/wjg.v12.i42.6771] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
657 Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol 2015; 21(12): 3462-3471 [PMID: 25834310 DOI: 10.3748/wjg.v21.i12.3462] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
658 Di Costanzo GG, Tortora R, De Luca M, Galeota Lanza A, Lampasi F, Tartaglione MT, Picciotto FP, Imparato M, Mattera S, Cordone G. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30:446. [PMID: 23307255 DOI: 10.1007/s12032-012-0446-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
659 Gan W, Yi Y, Fu Y, Huang J, Lu Z, Jing C, Fan J, Zhou J, Qiu S. Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study. J Cancer 2018;9:148-56. [PMID: 29290780 DOI: 10.7150/jca.22246] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
660 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
661 Ardito F, Famularo S, Aldrighetti L, Grazi GL, DallaValle R, Maestri M, Jovine E, Ruzzenente A, Baiocchi GL, Ercolani G, Griseri G, Frena A, Zanus G, Zimmitti G, Antonucci A, Crespi M, Memeo R, Romano F, Giuliante F; HE.RC.O.LE.S. Group. The Impact of Hospital Volume on Failure to Rescue after Liver Resection for Hepatocellular Carcinoma: Analysis from the HE.RC.O.LE.S. Italian Registry. Ann Surg 2020;272:840-6. [PMID: 32889868 DOI: 10.1097/SLA.0000000000004327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
662 Memet I, Tsalkidou E, Tsaroucha AK, Lambropoulou M, Chatzaki E, Trypsianis G, Schizas D, Pitiakoudis M, Simopoulos C. Autotaxin Expression in Hepatocellular Carcinoma. J Invest Surg 2018;31:359-65. [PMID: 28598712 DOI: 10.1080/08941939.2017.1331280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
663 Ray CE Jr, Brown AC, Green TJ, Winston H, Curran C, Kreidler SM, Glueck DH, Rochon PJ. Survival outcomes in patients with advanced hepatocellular carcinoma treated with drug-eluting bead chemoembolization. AJR Am J Roentgenol 2015;204:440-7. [PMID: 25615768 DOI: 10.2214/AJR.14.12844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
664 Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget 2017;8:48303-12. [PMID: 28430638 DOI: 10.18632/oncotarget.15684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
665 Wang Y, Liu H, Liang D, Huang Y, Zeng Y, Xing X, Xia J, Lin M, Han X, Liao N, Liu X, Liu J. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. J Proteomics 2017;150:230-41. [PMID: 27693406 DOI: 10.1016/j.jprot.2016.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
666 Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25. [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3] [Cited by in Crossref: 552] [Cited by in F6Publishing: 493] [Article Influence: 36.8] [Reference Citation Analysis]
667 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
668 Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol. 2011;54:108-114. [PMID: 21047696 DOI: 10.1016/j.jhep.2010.06.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
669 Orlacchio A, Gasparrini F, Lenci I, Gagliardi MG, Spada M, Guazzaroni M, Ciccarese G, Angelico M. Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient. Radiol Case Rep 2020;15:2602-6. [PMID: 33088372 DOI: 10.1016/j.radcr.2020.09.056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
670 Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101:524-532. [PMID: 16542289 DOI: 10.1111/j.1572-0241.2006.00443.x] [Cited by in Crossref: 230] [Cited by in F6Publishing: 234] [Article Influence: 14.4] [Reference Citation Analysis]
671 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
672 Müller C, Schöniger-hekele M, Schernthaner R, Renner B, Peck-radosavljevic M, Brichta A, Wrba F, Posch M, Bauer P, Ferenci P, Gangl A. Percutaneous ethanol instillation therapy for hepatocellular carcinoma – a randomized controlled trial. Wien Klin Wochenschr 2008;120:608-18. [DOI: 10.1007/s00508-008-1086-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
673 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
674 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]